Antigen binding domains and methods of use thereof
By designing antibodies or antigen-binding fragments that specifically bind human endothelial mucin to CAR-T cells, the problem of lack of targets in AML therapy is solved, and efficient killing of AML cells and protection of normal cells is achieved.
Patent Information
- Application Number
- CN202380034192.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-20
- Filing Date
- 2023-04-20
- Publication Date
- 2024-11-22
AI Technical Summary
Developing CAR therapies for acute myeloid leukemia (AML) faces the problem of lack of targets, making it difficult to specifically target tumor cells without damaging normal cells.
Provides antibody or antigen-binding fragments that specifically bind to human endothelial mucin (EMCN), containing specific variable heavy and light chain regions for designing chimeric antigen receptors (CARs) to enhance CAR-T cell pairs Killing activity of AML cells.
By specifically binding to EMCN, CAR-T cells can effectively kill targeted AML cells, reduce damage to normal cells, and improve the targeting and safety of AML therapy.
Smart Images

Figure CN119013306A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 333,064, filed on April 20, 2022, which is hereby incorporated by reference in its entirety.
[0003] Sequence Listing
[0004] This application includes a sequence listing, which has been submitted by EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy was created on XX / XX / 20XX, is named XXXXXUS_sequencelisting.txt, and is X,XXX,XXX bytes in size. Background Art
[0005] Adoptive cell therapy based on chimeric antigen receptor (CAR) is used to redirect the specificity and function of immune reactive cells (such as T cells), and has shown efficacy in patients with lymphoid malignancies (Pule et al., "Natural Medicine (Nat.Med.)" (14): 1264-1270 (2008); Maude et al., "New England Journal of Medicine (N Engl J Med.)" (371): 1507-17 (2014); Brentjens et al., "Sci Transl Med. (5): 177ra38 (2013)). CAR T cells have been shown to induce complete remission in patients with malignant tumors expressing CD19, whose chemotherapy has led to drug resistance and tumor progression. The success of CD19CAR therapy has brought hope for the treatment of other blood malignancies (such as acute myeloid leukemia (AML)). Acute myeloid leukemia is the most common acute leukemia in adults. AML is a cancer of the myeloid blood cells, characterized by the rapid growth of abnormal cells that accumulate in the bone marrow and blood, and interfere with normal blood cells. Sometimes, AML can spread to the brain, skin, or gums. Standard chemotherapy treatment for AML has not changed substantially in the past 40 years (Pulte et al., 2008), and overall survival remains short.
[0006] One challenge in developing CAR therapy for AML is the lack of suitable targets. The ability to identify appropriate CAR targets is important for effectively targeting and treating tumors without damaging normal cells that express the same target antigen. Therefore, there is still a need for CAR-T cell-based AML therapies that target AML cells without targeting normal cells or tissues. Summary of the invention
[0007] Provided herein is an isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising:
[0008] a variable heavy chain (VH) region comprising a VH complementary region 1 (CDRH1) having the amino acid sequence of SEQ ID NO: 1, a VH complementary region 2 (CDRH2) having the amino acid sequence of SEQ ID NO: 6, and a VH complementary region 3 (CDRH3) having the amino acid sequence of SEQ ID NO: 8; and
[0009] A variable light chain (VL) region comprising a VL complementary region L (CDRL1) having the amino acid sequence of SEQ ID NO:9, a VL complementary region 2 (CDRL2) having the amino acid sequence of SEQ ID NO:10, and a VL complementary region 3 (CDRL3) having the amino acid sequence of SEQ ID NO:11, wherein the antibody or antigen-binding fragment thereof is humanized.
[0010] Also provided herein is an isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising: a variable heavy chain (VH) region comprising a VH complementary region 1 (CDRH1) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-5, a VH complementary region 2 (CDRH2) having an amino acid sequence of SEQ ID NO: 7, and a VH complementary region 3 (CDRH3) having an amino acid sequence of SEQ ID NO: 8; and a variable light chain (VL) region comprising a VL complementary region L (CDRL1) having an amino acid sequence of SEQ ID NO: 9, a VL complementary region 2 (CDRL2) having an amino acid sequence of SEQ ID NO: 10, and a VL complementary region 3 (CDRL3) having an amino acid sequence of SEQ ID NO: 11, wherein the antibody or antigen-binding fragment thereof is humanized.
[0011] Also provided herein is an isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising: a variable heavy chain (VH) region comprising a VH complementary region 1 (CDRH1) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-4, a VH complementary region 2 (CDRH2) having an amino acid sequence of SEQ ID NO: 7, and a VH complementary region 3 (CDRH3) having an amino acid sequence of SEQ ID NO: 8; and a variable light chain (VL) region comprising a VL complementary region L (CDRL1) having an amino acid sequence of SEQ ID NO: 9, a VL complementary region 2 (CDRL2) having an amino acid sequence of SEQ ID NO: 10, and a VL complementary region 3 (CDRL3) having an amino acid sequence of SEQ ID NO: 11.
[0012] In some aspects, the CDRH1 is as shown in SEQ ID NO:2.
[0013] In some aspects, the VH region has an amino acid sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15.
[0014] In some aspects, the VH region has the amino acid sequence as shown in SEQ ID NO:12.
[0015] In some aspects, the VH region has an amino acid sequence selected from the group consisting of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19.
[0016] In some aspects, the VH region has the amino acid sequence as shown in SEQ ID NO:16.
[0017] In some aspects, the VL has the amino acid sequence as shown in SEQ ID NO:20.
[0018] Also provided herein is an isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH comprises: a heavy chain complementary determining region 1 (CDR-H1), a heavy chain complementary determining region 2 (CDR-H2), and a heavy chain complementary determining region 3 (CDR-H3) comprised within a VH region amino acid sequence selected from the group consisting of SEQ ID NOs: 12-19, and the VL comprises: a light chain complementary determining region 1 (CDR-L1), a light chain complementary determining region 2 (CDR-L2), and a light chain complementary determining region 3 (CDR-L3) comprised within a VL region amino acid sequence of SEQ ID NO: 20.
[0019] Also provided herein is an isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising a variable heavy chain (VH) region and a variable light chain (VL) region, wherein the VL has an amino acid sequence as shown in SEQ ID NO: 20.
[0020] Also provided herein is an isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising a variable heavy chain (VH) region and a variable light chain (VL) region, wherein the VH has an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19.
[0021] In some aspects, the VH has an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15. In some aspects, the VH region has an amino acid sequence as shown in SEQ ID NO:12.
[0022] In some aspects, the VH has an amino acid sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19. In some aspects, the VH region has an amino acid sequence as shown in SEQ ID NO:16.
[0023] In some aspects, the VL has the amino acid sequence as shown in SEQ ID NO:20.
[0024] In some aspects, the antibody or its antigen binding fragment is an antigen binding fragment. In some aspects, the antigen binding fragment includes a F(ab) fragment, a F(ab') fragment or a single chain variable fragment (scFV). In some aspects, the antigen binding fragment includes a single chain variable fragment (scFv).
[0025] In some aspects, the VH and VL of the scFv are separated by a peptide linker. In some aspects, the antigen binding domain comprises a structure VH-L-VL or VL-L-VH, wherein VH is a heavy chain variable domain, L is a peptide linker, and VL is a light chain variable domain. In some aspects, the peptide linker comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 21-37.
[0026] In some aspects, the scFv comprises an amino acid sequence selected from the group consisting of: SEQ ID No: 68, 70, 72 and 74.
[0027] Also provided herein is a chimeric protein comprising an antibody or antigen-binding fragment thereof as provided herein, and a heterologous molecule or portion.
[0028] In some aspects, the chimeric protein is an antibody-drug conjugate and the heterologous molecule or moiety comprises the therapeutic agent.
[0029] In some aspects, the chimeric protein is a chimeric antigen receptor (CAR), and the heterologous molecule or portion comprises a polypeptide selected from the group consisting of: a transmembrane domain, one or more intracellular signaling domains, a hinge domain, a spacer, one or more peptide linkers, and combinations thereof. In some aspects, the CAR comprises a transmembrane domain. In some aspects, the CAR includes one or more intracellular signaling domains.
[0030] In some aspects, the CAR is an activating CAR that includes one or more intracellular signaling domains that stimulate an immune response.
[0031] In some aspects, the CAR is an inhibitory CAR comprising one or more intracellular inhibitory domains that inhibit immune responses. In some aspects, the intracellular inhibitory domain includes an enzymatic inhibitory domain. In some aspects, the intracellular inhibitory domain includes an intracellular inhibitory co-signaling domain.
[0032] In some aspects, the CAR includes a spacer between the antigen binding domain and the transmembrane domain. In some aspects, the spacer has an amino acid sequence selected from the group consisting of SEQ ID NO: 41-52.
[0033] Also provided herein is a composition comprising an antibody or antigen-binding fragment thereof as provided herein or a chimeric protein as provided herein and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof.
[0034] Also provided herein is an engineered nucleic acid encoding an antibody or antigen-binding fragment as provided herein or a chimeric protein as provided herein.
[0035] Also provided herein is an expression vector comprising an engineered nucleic acid encoding any one of the antibodies or antigen-binding fragments provided herein.
[0036] Also provided herein is a composition comprising an engineered nucleic acid as provided herein or an expression vector as provided herein and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof.
[0037] Also provided herein is a method of preparing an engineered cell, the method comprising transducing an isolated cell with an engineered nucleic acid as provided herein or an expression vector as provided herein.
[0038] Also provided herein is an isolated cell comprising an engineered nucleic acid as provided herein, an expression vector as provided herein, or a composition as provided herein.
[0039] Also provided herein is an engineered cell population expressing an engineered nucleic acid as provided herein or an expression vector as provided herein.
[0040] Also provided herein is an isolated cell comprising an antigen-binding fragment as provided herein or a chimeric protein as provided herein.
[0041] Also provided herein is an engineered cell population expressing an antigen binding fragment as provided herein or a chimeric protein as provided herein.
[0042] In some aspects, the chimeric protein is recombinantly expressed by a cell or a population of cells. In some aspects, the chimeric protein is expressed from a vector or a selected locus of the genome of the cell.
[0043] In some aspects, the cell or cell group also includes one or more tumor-targeted chimeric receptors expressed on the cell surface. In some aspects, each of the one or more tumor-targeted chimeric receptors is a chimeric antigen receptor (CAR) or an engineered T cell receptor.
[0044] In some aspects, the cell or cell population is selected from the group consisting of: T cells, CD8+T cells, CD4+T cells, γ-δT cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, virus-specific T cells, natural killer T (NKT) cells, natural killer (NK) cells, B cells, tumor infiltrating lymphocytes (TILs), innate lymphoid cells, mast cells, eosinophils, basophils, neutrophils, bone marrow cells, macrophages, monocytes, dendritic cells, erythrocytes, platelet cells, human embryonic stem cells (ESCs), ESC-derived cells, pluripotent stem cells, mesenchymal stromal cells (MSCs), induced pluripotent stem cells (iPSCs), and iPSC-derived cells.
[0045] In some aspects, the cells are autologous. In some aspects, the cells are allogeneic.
[0046] Also provided herein is a pharmaceutical composition comprising an effective amount of a cell or engineered cell population as provided herein and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof.
[0047] Also provided herein is a pharmaceutical composition comprising an effective amount of a genetically modified cell expressing an antigen-binding fragment as provided herein or a chimeric protein as provided herein and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof.
[0048] In some aspects, the pharmaceutical composition is used to treat and / or prevent tumors.
[0049] Also provided herein is a method of treating a subject in need thereof, the method comprising administering a therapeutically effective dose of any of the compositions provided herein or the cells provided herein.
[0050] Also provided herein is a method of stimulating a cell-mediated immune response against tumor cells in a subject, the method comprising administering a therapeutically effective dose of any of the compositions provided herein or the cells provided herein to a subject having a tumor.
[0051] In some aspects, the method comprises administering a cell or a population of cells as provided herein to a subject, wherein the cell or the population of cells expresses a chimeric protein comprising an activating CAR as provided herein.
[0052] Also provided herein is a method for suppressing a cell-mediated immune response against tumor cells in a subject, the method comprising administering a therapeutically effective dose of a composition as provided herein or any of a cell as provided herein to a subject with a tumor. In some aspects, the method comprises administering a cell or cell population as provided herein to a subject, wherein the cell or cell population expresses a chimeric protein comprising an inhibitor as provided herein.
[0053] Also provided herein is a method of treating a subject having a tumor, the method comprising administering a therapeutically effective dose of any of the compositions provided herein or the cells provided herein.
[0054] Also provided herein is a kit for treating and / or preventing a tumor, the kit comprising the chimeric protein as provided herein.
[0055] In some aspects, the kit further comprises written instructions for using the chimeric protein to generate one or more antigen-specific cells for treating and / or preventing a tumor in a subject.
[0056] Also provided herein is a kit for treating and / or preventing a tumor, the kit comprising a cell or cell population as provided herein. In some aspects, the kit further comprises written instructions for using the cell to treat and / or prevent a tumor in a subject.
[0057] Also provided herein is a kit for treating and / or preventing tumors, the kit comprising an engineered nucleic acid as provided herein. In some aspects, the kit also comprises written instructions for using the nucleic acid to generate one or more antigen-specific cells for treating and / or preventing a tumor in a subject.
[0058] Also provided herein is a kit for treating and / or preventing tumors, the kit comprising a vector as provided herein. In some aspects, the kit also comprises written instructions for using the vector to produce one or more antigen-specific cells for treating and / or preventing tumors in a subject.
[0059] Also provided herein is a kit for treating and / or preventing a tumor, the kit comprising a composition as provided herein. In some aspects, the kit further comprises written instructions for using the composition to treat and / or prevent a tumor in a subject. BRIEF DESCRIPTION OF THE DRAWINGS
[0060] This patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0061] These and other features, aspects and advantages of the present disclosure will become better understood with reference to the following description and accompanying drawings.
[0062] Figure 1 The killing activity of T cells expressing the humanized anti-EMCN CAR of the present disclosure on target cells expressing EMCN was shown.
[0063] Figure 2 CAR expression of NK cells transduced with various anti-EMCN CARs is shown.
[0064] Figure 3 The killing activity of NK cells transduced with various anti-EMCN CARs against target cells expressing EMCN is shown. DETAILED DESCRIPTION
[0065] Unless otherwise indicated, the practice of the present disclosure will utilize conventional methods of molecular biology, chemistry, biochemistry, virology, and immunology within the skill of the art. Such techniques are fully explained in the literature. See, for example, Hepatitis C Viruses: Genomes and Molecular Biology (SLTan, ed., Taylor and Francis, 2006); Fundamental Virology, 第 3rd edition, Volumes I and II (BN Fields and DMKnipe, eds.); Handbook of Experimental Immunology, Volumes I-IV (DM Weir and CC Blackwell, eds., Blackwell Scientific Publications); A Lehninger, Biochemistry (Worth Publishers, Inc., current edition); Sambrook et al., Molecular Cloning: A Laboratory Manual (3rd edition, 2001); Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academic Press, Inc.).
[0066] definition
[0067] Unless otherwise defined, all technical terms, marks and other scientific terms used herein are intended to have the meanings commonly understood by those skilled in the art. In some cases, the terms with commonly understood meanings are defined herein for clarity and / or quick reference purposes, and such definitions contained herein may not necessarily be understood to represent differences commonly understood in the art. The techniques and procedures described or quoted herein are generally understood by those skilled in the art and are generally adopted using conventional methods, for example, Sambrook et al., "Molecular Cloning: Laboratory Manual" 4th edition (2012) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, and the widely used molecular cloning methods described. When appropriate, unless otherwise specified, the procedures involving the use of commercially available kits and reagents are generally carried out according to the schemes and conditions defined by the manufacturer.
[0068] As used herein, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. The terms "include", "such as", and the like are intended to convey inclusion but not limitation, unless the context clearly dictates otherwise.
[0069] As used herein, the term "comprising" also expressly encompasses the embodiments of "consisting of" and "consisting essentially of the recited elements," unless expressly stated otherwise.
[0070] The term "about" refers to and encompasses a specified value and a range around that value. In certain embodiments, the term "about" refers to a specified value ± 10%, ± 5%, or ± 1%. In certain embodiments, where applicable, the term "about" refers to a specified value ± one standard deviation of that value.
[0071] As used herein, the term "stimulate cell-mediated immune response" or "stimulate immune response" refers to a signal that generates an immune response caused by one or more cell types or cell groups. Immunostimulatory activity may include proinflammatory activity. In various embodiments, the immune response occurs after activation of immune cells (e.g., T cells or NK cells), or concomitantly mediated by receptors (including but not limited to CD28, CD137 (4-1BB), OX40, CD40 and ICOS) and their corresponding ligands (including B7-1, B7-2, OX-40L and 4-1BBL). Such polypeptides may be present in a tumor microenvironment and may activate an immune response to tumor cells. In multiple embodiments, promoting, stimulating or exciting proinflammatory polypeptides and / or their ligands may enhance the immune response of immunoreactive cells. Without being bound by a particular theory, receiving multiple stimulatory signals (e.g., co-stimulation) is important for establishing a strong and long-lasting cell-mediated immune response (such as a T cell-mediated immune response), for which, in the absence of co-stimulatory signals, T cells can be suppressed and unresponsive to antigens (also known as "T cell anergy"). Although the effects of various co-stimulatory signals, especially in combination with each other, can vary and are still only partially understood, co-stimulation generally causes increased gene expression to produce long-term, proliferative and apoptotic tolerant cells, such as T cells or NK cells, which respond strongly to antigens, for example in terms of complete and / or sustained eradication of target cells expressing cognate antigens.
[0072] As used herein, the term "chimeric antigen receptor" or alternatively "CAR" refers to a recombinant polypeptide construct comprising at least an extracellular antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain (also referred to herein as an "intracellular signaling domain") including a functional signaling domain.
[0073] As used herein, the term "activating CAR" or "aCAR" refers to a CAR construct / construct capable of inducing changes in signal transduction or protein expression in activated CAR-expressing cells, which upon binding to a cognate aCAR ligand initiates, activates, stimulates or increases an immune response.
[0074] As used herein, the term "inhibitory CAR" or "iCAR" refers to a CAR construct / structure capable of inducing signal transduction or protein expression changes in an inhibitory CAR-expressing cell, which, when bound to a cognate iCAR ligand, prevents, attenuates, inhibits, reduces, decreases, inhibits or prevents an immune response, such as reducing the activation of an immunoreactive cell that receives or has received one or more stimulatory signals (including a co-stimulatory signal).
[0075] As used herein, the term "intracellular signaling domain" refers to a functional portion of a protein that acts by transmitting information within the cell to regulate cellular activity via a defined signaling pathway, either by producing second messengers or by acting as an effector in response to such messengers.
[0076] As used herein, the term "extracellular antigen binding domain" or "antigen binding domain" (ABD) refers to a polypeptide sequence or polypeptide complex that specifically recognizes or binds to a given antigen or epitope, such as a polypeptide sequence or polypeptide complex portion of a chimeric protein described herein that provides EMCN specific binding. The ABD (or antibody, antigen binding fragment and / or chimeric protein comprising them) is said to "recognize" the epitope (or more generally, the antigen) to which the ABD specifically binds, and the epitope is said to be the "recognition specificity" or "binding specificity" of the ABD. The ABD is said to bind to its specific antigen or epitope with a specific affinity. As described herein, "affinity" refers to the strength of the interaction of non-covalent intermolecular forces between one molecule and another. Affinity, i.e., the strength of the interaction, can be expressed as a dissociation equilibrium constant (KD), where a smaller KD value means a stronger interaction between molecules. The KD value of an antibody construct is measured by methods well known in the art, including, but not limited to, biolayer interferometry (e.g., ), surface plasmon resonance (SPR) techniques (e.g. ) and cell binding assays (e.g., flow cytometry). Specific binding as assessed by affinity can refer to a binding molecule with an affinity between an ABD and its cognate antigen or epitope, where KD 值低于10 -6 M、10 -7 M、10 -8 M、10 -9 M 或10 -10M. Specific binding may also include recognition and binding of a biomolecule of interest (e.g., a polypeptide) while non-specifically recognizing and binding other molecules in a sample (e.g., a biological sample) that naturally contains the polypeptide of the present disclosure. In certain embodiments, specific binding refers to binding between an ABD, an antibody, or an antigen-binding fragment and an epitope or antigen or antigenic determinant in a manner that can be displaced or competed with a second agent of the same or similar epitope, antigen, or antigenic determinant.
[0077] ABD can be an antibody. As used herein, the term "antibody" refers to a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds to an antigen. Antibodies can be polyclonal or monoclonal, multi-chain or single-chain, or complete immunoglobulins, and can be derived from natural or recombinant sources. Antibodies can be tetramers of immunoglobulin molecules.
[0078] ABD can be an antigen binding fragment of an antibody. As used herein, the term "antigen binding fragment" refers to at least a portion of a complete antibody or a recombinant variant thereof, which is sufficient to confer recognition and specific binding of the antigen binding fragment to a target (such as an antigen or epitope). Examples of antigen binding fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv, scFv, linear antibodies, single domain antibodies such as sdAb (VL or VH), camel VHH domains, and multispecific antibodies formed by antigen binding fragments, such as bivalent fragments of two Fab fragments connected by disulfide bonds at the hinge region, and CDRs or other epitope binding fragments of the separation of antibodies. Antigen binding fragments can also be incorporated into single domain antibodies, giant antibodies, microantibodies, nanoantibodies, intrabodies, diabodies, tribodies, tetrabodies, v-NARs and bis-scFvs (see, for example, Hollinger and Hudson, "Nature Biotechnology (Nature Biotechnology)" 23: 1126-1 136, 2005). Antigen binding fragments can also be grafted into scaffolds based on polypeptides such as type III fibronectin (Fn3) (see US Pat. No. 6,703,199, which describes fibronectin polypeptide minibodies).
[0079] The number of ABDs in a binding molecule (such as a chimeric protein as described herein) defines the "valence" of the binding molecule. A binding molecule with a single ABD is "monovalent". A binding molecule with multiple ABDs is referred to as "multivalent". A multivalent binding molecule with two ABDs is "bivalent". A multivalent binding molecule with three ABDs is "trivalent". A multivalent binding molecule with four ABDs is "tetravalent". In various multivalent embodiments, all multiple ABDs have the same recognition specificity and can be referred to as "monospecific multivalent" binding molecules. In other multivalent embodiments, at least two of the multiple ABDs have different recognition specificities. Such binding molecules are multivalent and "multispecific". In a multivalent embodiment in which ABDs have two recognition specificities in common, the binding molecule is "bispecific". In a multivalent embodiment in which ABDs have three recognition specificities in common, the binding molecule is "trispecific". In a multivalent embodiment in which ABDs have multiple recognition specificities for different epitopes present on the same antigen in common, the binding molecule is "multiparatopic". Multivalent embodiments in which the ABD jointly recognize two epitopes on the same antigen are "biparatopic".
[0080] In various multivalent embodiments, the multivalency of the binding molecule improves the affinity of the binding molecule for a specific target. As described herein, "avidity" refers to the total strength of the interaction between two or more molecules (e.g., a multivalent binding molecule for a specific target), where avidity is the cumulative interaction strength provided by the affinities of multiple ABDs. Avidity can be measured by the same method as used to determine affinity, as described above. In certain embodiments, the affinity of the binding molecule for a specific target makes the interaction a specific binding interaction, where the affinity between the two molecules has less than 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 In some embodiments, the affinity of the binding molecule for a specific target has a KD value such that the interaction is a specific binding interaction, wherein the one or more affinities of the individual ABDs do not have a KD value consistent with the specific binding of their respective antigens or epitopes to themselves. In some embodiments, the avidity is the cumulative interaction strength provided by the affinities of multiple ABDs for a single antigen on a common specific target or complex (such as a single antigen present on a single cell). In some embodiments, the avidity is the cumulative interaction strength provided by the affinities of multiple ABDs for a single epitope on a common single antigen.
[0081] As used herein, the term "single-chain variable fragment" or "scFv" refers to a fusion protein comprising at least one antigen-binding fragment comprising a variable region of a light chain and at least one antigen-binding fragment comprising a variable region of a heavy chain, wherein the light chain and heavy chain variable regions are continuously connected via a short flexible polypeptide linker, capable of being expressed as a single-chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived. Unless otherwise specified, as used herein, scFv can have VL and VH variable regions in any order, for example, with respect to the N-terminus and C-terminus of the polypeptide, the scFv can include VL-linker-VH or can include VH-linker-VL.
[0082] As used herein, "variable region" refers to variable sequences derived from recombination events, such as after recombination of V, J and / or D segments of immunoglobulin genes in B cells or T cell receptor (TCR) genes in T cells. In immunoglobulin genes, variable regions are usually defined by the antibody chains from which they are derived, for example, VH refers to the variable region of the antibody heavy chain, and VL refers to the variable region of the antibody light chain. The selected VH and the selected VL can be associated together to form an antigen binding domain, which confers antigen specificity and binding affinity.
[0083] As used herein, the term "complementarity determining region" or "CDR" refers to sequences within the antibody variable regions VH and VL that confer antigen specificity and binding affinity. For example, typically, there are three CDRs (e.g., HCDR1, HCDR2, and HCDR3) in each heavy chain variable region and three CDRs (LCDR1, LCDR2, and LCDR3) in each light chain variable region. The precise amino acid sequence boundaries of a given CDR can be determined using any of a variety of well-known schemes, including those described in Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th ed., National Institutes of Health, Public Health Service, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., (1997) JMB 273, 927-948 ("Chothia" numbering scheme), or a combination thereof. According to the Kabat numbering scheme, in some embodiments, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31 to 35 (HCDR1), 50 to 65 (HCDR2), and 95 to 102 (HCDR3); while the CDR amino acid residues in the light chain variable domain (VL) are numbered 24 to 34 (LCDR1), 50 to 56 (LCDR2), and 89 to 97 (LCDR3). According to the Chothia numbering scheme, in some embodiments, the CDR amino acids in VH are numbered 26 to 32 (HCDR1), 52 to 56 (HCDR2), and 95 to 102 (HCDR3); while the CDR amino acid residues in VL are numbered 26 to 32 (LCDR1), 50 to 52 (LCDR2), and 91 to 96 (LCDR3). In the combined Kabat and Chothia numbering schemes, in some embodiments, the CDRs correspond to amino acid residues that are part of a Kabat CDR, a Chothia CDR, or both. For example, in some embodiments, the CDRs correspond to amino acid residues 26 to 35 (HCDR1), 50 to 65 (HCDR2), and 95 to 102 (HCDR3) in VH (e.g., mammalian VH, e.g., human VH); amino acid residues 24 to 34 (LCDR1), 50 to 56 (LCDR2), and 89 to 97 (LCDR3) in VL (e.g., mammalian VL, e.g., human VL). In various embodiments, the CDRs are mammalian sequences, including but not limited to mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In preferred embodiments, the CDRs are human sequences.In various embodiments, the CDRs are naturally occurring sequences.
[0084] As used herein, the term "framework region" or "FR" refers to a sequence that is generally conserved within the variable regions VH and VL of an antibody, which serves as a scaffold for interspersed CDRs, typically arranged in FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (from N-terminus to C-terminus). In various embodiments, FR is a mammalian sequence, including but not limited to mouse sequences, rat sequences, hamster sequences, rabbit sequences, camel sequences, monkey sequences, goat sequences, and human sequences. In specific embodiments, FR is a human sequence. In various embodiments, FR is a naturally occurring sequence. In various embodiments, FR is a synthetic sequence, including but not limited to a rationally designed sequence.
[0085] As used herein, the term "antibody heavy chain" refers to the larger of the two types of polypeptide chains present in antibody molecules in their naturally occurring conformations, and which generally determines the class to which the antibody belongs.
[0086] As used herein, the term "antibody light chain" refers to the smaller of the two types of polypeptide chains present in antibody molecules in their naturally occurring conformations. Kappa (κ) and lambda (λ) light chains refer to the two major antibody light chain isotypes.
[0087] As used herein, the term "recombinant antibody" refers to an antibody produced using recombinant DNA technology, for example, such as an antibody expressed by a bacteriophage or yeast expression system. The term should also be considered to mean an antibody produced by synthesizing a DNA molecule encoding the antibody (and the DNA molecule expresses the antibody protein) or a specified antibody amino acid sequence, wherein the DNA or amino acid sequence is obtained using recombinant DNA or amino acid sequence technology available and well known in the art.
[0088] As used herein, the term "antigen" or "Ag" refers to a molecule that provokes an immune response. This immune response may involve antibody production or activation of specific immune competent cells or both. It will be appreciated by those skilled in the art that any macromolecule, including almost all proteins or peptides, can be used as an antigen.
[0089] As used herein, the term "anti-tumor effect" or "anti-tumor activity" refers to a biological effect that can be manifested by various means, including but not limited to, for example, a reduction in tumor volume, a reduction in the number of tumor cells, a reduction in the number of metastases, an increase in life expectancy, a reduction in tumor cell proliferation, a reduction in tumor cell survival, or an improvement in various physiological symptoms associated with cancer conditions. "Anti-tumor effect" can also be demonstrated by the ability of the peptides, polynucleotides, cells and antibodies of the present disclosure to prevent tumorigenesis in the first place, such as in preventive therapy or treatment.
[0090] As used herein, the term "autologous" refers to any material from the same subject that is subsequently reintroduced into the subject.
[0091] As used herein, the term "allogeneic" refers to any material from a different animal of the same species as the subject into which the material is introduced. Two or more subjects are considered to be allogeneic to each other when the genes at one or more loci are not identical. In some embodiments, allogeneic material from individuals of the same species may be genetically different enough, such as different enough in specific genes such as MHC alleles, to interact antigenically. In some embodiments, allogeneic material from individuals of the same species may be genetically similar enough, such as similar enough in specific genes such as MHC alleles, so that antigenic interaction does not occur.
[0092] The isolated nucleic acid molecules of the present disclosure include any nucleic acid molecules or fragments thereof encoding the polypeptides of the present disclosure. Such nucleic acid molecules need not be 100% homologous or identical to the endogenous nucleic acid sequence, but will typically exhibit basic identity. Nucleic acids having "basic identity" or "basic homology" with endogenous sequences are typically capable of hybridizing with at least one chain of a double-stranded nucleic acid molecule. As used herein, "hybridization" refers to pairing under various stringent conditions to form a double-stranded molecule between a complementary polynucleotide sequence (e.g., a gene as described herein) or a portion thereof. For example, a stringent salt concentration can be less than about 750mM NaCl and 75mM trisodium citrate, less than about 500mM NaCl and 50mM trisodium citrate, or less than about 250mM NaCl and 25mM trisodium citrate. Low stringency hybridization can be obtained in the absence of an organic solvent (e.g., formamide), while high stringency hybridization can be obtained in the presence of at least about 35% formamide or at least about 50% formamide. Stringent temperature conditions will generally include a temperature of at least about 30° C., at least about 37° C., or at least about 42° C. Various other parameters, such as hybridization time, concentration of detergent (e.g., sodium dodecyl sulfate (SDS)), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Different levels of stringency can be achieved by combining these different conditions as desired.
[0093] "Substantially identical" or "substantially homologous" means that a polypeptide or nucleic acid molecule exhibits at least about 50% homology or identity to a reference amino acid sequence (e.g., any of the amino acid sequences described herein) or a nucleic acid sequence (e.g., any of the nucleic acid sequences described herein). Preferably, such a sequence is at least about 60%, about 80%, about 85%, about 90%, about 95%, about 99%, or about 100% homologous or identical to the sequence used for comparison at the amino acid level or nucleic acid. Sequence identity is typically measured using sequence analysis software (e.g., sequence analysis software packages, BLAST, BESTFIT, GAP, or PILEUP / PRETTYBOX programs from the Genetics Computer Group, University of Wisconsin Biotechnology Center (1710 University Avenue, Madison, Wis. 53705). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and / or other modifications. Conservative substitutions generally include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamic acid; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary method of determining the degree of identity, the BLAST program can be used, where probability scores between e-3 and e-100 indicate closely related sequences.
[0094] As used herein, the term "coding" refers to a polynucleotide that serves as a template for synthesizing other polymers and macromolecules in a biological process and has a determined nucleotide sequence (e.g., rRNA, tRNA, and mRNA) or a determined amino acid sequence, such as the inherent properties of a specific nucleotide sequence in a gene, cDNA, or mRNA, and the resulting biological properties. Therefore, if the transcription and translation of the mRNA corresponding to a gene produces a protein in a cell or other biological system, the gene, cDNA, or RNA encodes the protein. The nucleotide sequence is identical to the mRNA sequence and is usually provided in the sequence table. The non-coding strand used as a template for the transcription of a gene or cDNA can be referred to as encoding a protein or other products of the gene or cDNA. Unless otherwise specified, "nucleotide sequences encoding amino acid sequences" include all nucleotide sequences that are degenerate forms and encode the same amino acid sequence. The phrase encoding a protein or RNA nucleotide sequence can also include introns, to the extent that the nucleotide sequence encoding a protein can contain introns in a certain form.
[0095] As used herein, the term "ligand" refers to a molecule that binds to a receptor. In particular, a ligand binds to a receptor on another cell, allowing cell-cell recognition and / or interaction.
[0096] The terms "effective amount" and "therapeutically effective amount" are used interchangeably herein and refer to an amount of a compound, formulation, material or composition as described herein that is effective for achieving a specific biological outcome. In some embodiments, an "effective amount" or "therapeutically effective amount" is an amount sufficient to arrest, improve or inhibit the continued proliferation, growth or metastasis of a target disease or disorder (e.g., a myeloid disorder).
[0097] As used herein, the term "immune response cell" refers to a cell or progenitor cell or its progeny that functions in an immune response (e.g., an immune effector response). Examples of immune effector cells include, but are not limited to, α / βT cells, γ / δT cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and myeloid-derived phagocytes.
[0098] As used herein, the term "immune effector response" or "immune effector function" refers to a function or response of an immunoreactive cell that, for example, enhances or promotes an immune attack on a target cell. For example, an immune effector function or response may refer to the property of a T cell or NK cell that promotes killing of a target cell or inhibits its growth or proliferation. In the case of T cells, primary stimulation and co-stimulation are examples of immune effector functions or responses.
[0099] As used herein, the term "flexible polypeptide linker" or "linker" refers to a peptide linker composed of amino acids such as glycine and / or serine residues used alone or in combination to connect the variable heavy chain and variable light chain regions together. In one embodiment, the flexible polypeptide linker is a Gly / Ser linker and includes an amino acid sequence (Gly-Gly-Gly-Gly-Ser)n or (Gly-Gly-Gly-Ser)n, wherein n is a positive integer equal to or greater than 1. For example, n=1, n=2, n=3, n=4, n=5, n=6, n=7, n=8, n=9 or n=10. In some embodiments, the flexible polypeptide linker includes but is not limited to Gly4Ser or (Gly4Ser)3. In other embodiments, the linker includes a plurality of repeating units of (Gly2Ser), (GlySer) or (Gly3Ser). In some embodiments, the flexible polypeptide linker includes a Whitlow linker (e.g., GSTSGSGKPGSGEGSTKG [SEQ ID NO: 36]). Also included within the scope of the present disclosure are linkers such as those described in WO 2012 / 138475.
[0100] As used herein, the term "treatment (treat, treatment and treating)" refers to the reduction or improvement of the progress, severity and / or duration of a proliferative disease (e.g., cancer) caused by the administration of one or more therapies (e.g., one or more therapeutic agents of the present disclosure such as CAR), or one or more symptoms (preferably, one or more discernible symptoms) of a proliferative disorder. In some embodiments, reduction or improvement refers to the improvement of at least one measurable physical parameter of a proliferative disorder, such as the growth of a tumor, which is not necessarily perceived by the patient. In other embodiments, the terms "treatment (treat)", "treatment (treatment)" and "treatment (treating)" refer to physically (by, for example, stabilizing discernible symptoms), physiologically (by, for example, stabilizing physical parameters) or both inhibiting the progress of proliferative disorders. In some embodiments, reduction or improvement includes reduction or stabilization of tumor size or cancer cell counts.
[0101] As used herein, the term "subject" is intended to include a living organism (eg, mammal, human) in which an immune response can be elicited.
[0102] Other aspects of the disclosure are described in the following sections and are within the scope of the claimed invention.
[0103] Other interpretation conventions
[0104] The ranges recited herein should be understood as a simplification of all values within the range (including the endpoints). For example, a range of 1 to 50 should be understood to include any number, combination of numbers or subranges from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50.
[0105] Unless otherwise indicated, reference to a compound having one or more stereocenters is intended to refer to each and every stereoisomer and all combinations of stereoisomers thereof.
[0106] Endothelial mucin-specific antigen binding domain
[0107] The present disclosure provides an antigen binding domain (e.g., a single-chain variable fragment) that is bound to endothelial mucin (EMCN), a chimeric protein comprising an antigen binding domain that is bound to EMCN, and nucleic acids encoding such antigen binding domains and chimeric proteins. Without wishing to be bound by theory, EMCN is a sialic acid glycoprotein that interferes with the assembly of focal adhesion complexes and inhibits the interaction between cells and the extracellular matrix. The EMCN-specific antigen binding domain is bound to human EMCN (e.g., Uniprot Q9ULC0, which is incorporated herein by reference for all purposes) or an epitope fragment thereof. EMCN can be expressed on hematopoietic stem cells and progenitor cells (HSPC). EMCN can be expressed on cells that are generally considered to be healthy, such as healthy HSPC. EMCN-specific antibodies have been previously described, including CBFYE-0213, V.7.C7.1, L4B1, L5F12, L10B5, L3F12, L6H3, L6H10 (also referred to herein as Abl), L9H8, and L10F12, as described in J. Path., May 2002, 160(5):1669-1681, which is incorporated herein by reference for all purposes.
[0108] The present disclosure provides an EMCN-specific antigen-binding domain, which comprises one or more of the amino acid sequences listed in Table 1.
[0109] Table 1. EMCN-specific antigen binding domains
[0110]
[0111]
[0112] In some embodiments, the EMCN-specific antigen binding domain has a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH comprises a heavy chain complementary determining region 3 (CDR-H3), and the CDR-H3 has an amino acid sequence of RIKD (SEQ ID NO: 8). In some embodiments, the EMCN-specific antigen binding domain has a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH comprises a heavy chain complementary determining region 1 (CDR-H1), a heavy chain complementary determining region 2 (CDR-H2), and a heavy chain complementary determining region 3 (CDR-H3), wherein the amino acid sequences of the CDR-H1, the CDR-H2, and the CDR-H3 are contained within the VH region amino acid sequence selected from the group consisting of SEQ ID NO: 12-20. In some embodiments, the VH region has an amino acid sequence selected from the group consisting of SEQ ID NO: 12-15. In some embodiments, the VH region has an amino acid sequence of SEQ ID NO: 12. In some embodiments, the VH region has an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-19. In some embodiments, the VH region has an amino acid sequence of SEQ ID NO: 16. In some embodiments, the EMCN-specific antigen binding domain has a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH comprises a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of SEQ ID NO: 7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the EMCN-specific antigen-binding domain having the above-mentioned VH sequence may have a light chain complementary determining region 1 (CDR-L1), a light chain complementary determining region 2 (CDR-L2), and a light chain complementary determining region 3 (CDR-L3), wherein the amino acid sequences of CDR-L1, CDR-L2, and CDR-L3 are contained within the VL region amino acid sequence of SEQ ID NO: 20. In some embodiments, the EMCN-specific antigen-binding domain having the above-mentioned VH sequence may have a heavy chain complementary determining region 1 (CDR-L1) having an amino acid sequence of SEQ ID NO: 9, a heavy chain complementary determining region 2 (CDR-L2) having an amino acid sequence of SEQ ID NO: 10, and a heavy chain complementary determining region 3 (CDR-L3) having an amino acid sequence of SEQ ID NO: 11.
[0113] In some embodiments, the EMCN-specific antigen binding domain has a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VL comprises a light chain complementary determining region 1 (CDR-L1), a light chain complementary determining region 2 (CDR-L2), and a light chain complementary determining region 3 (CDR-L3), wherein the amino acid sequences of the CDR-L1, the CDR-L2, and the CDR-L3 are contained within the VL region amino acid sequence of SEQ ID NO: 20. In some embodiments, the EMCN-specific antigen binding domain has a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VL comprises a light chain complementary determining region 1 (CDR-L1) having an amino acid sequence of SEQ ID NO: 9, a light chain complementary determining region 2 (CDR-L2) having an amino acid sequence of SEQ ID NO: 10, and a light chain complementary determining region 3 (CDR-L3) having an amino acid sequence of SEQ ID NO: 11. In some embodiments, the EMCN-specific antigen-binding domain having the above-mentioned VL sequence may have a heavy chain complementary determining region 1 (CDR-H1), a heavy chain complementary determining region 2 (CDR-H2), and a heavy chain complementary determining region 3 (CDR-H3), wherein the amino acid sequences of the CDR-H1, the CDR-H2, and the CDR-H3 are contained in the VH region amino acid sequence selected from the group consisting of SEQ ID NOs: 12-20. In some embodiments, the EMCN-specific antigen-binding domain having the above-mentioned VL sequence may have a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence of SEQ ID NO: 2, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of WGNGN SEQ ID NO: 7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the EMCN-specific antigen-binding domain having the above-mentioned VL sequence may have a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence of SEQ ID NO: 3, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of WGNGN SEQ ID NO: 7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO: 8. In some embodiments, the EMCN-specific antigen-binding domain having the above-mentioned VL sequence may have a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence of SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of SEQ ID NO: 7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO: 8.In some embodiments, the EMCN-specific antigen binding domain having the above-mentioned VL sequence can have a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence of SEQ ID NO:5, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of WGNGN SEQ ID NO:7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO:8.
[0114] In some embodiments, the EMCN-specific antigen binding domain has a heavy chain variable (VH) region and a light chain variable (VL) region, wherein: (1) VH comprises a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence of SEQ ID NO:2, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of SEQ ID NO:7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO:8, and (2) VL comprises a light chain complementary determining region 1 (CDR-L1) having an amino acid sequence of SEQ ID NO:9, a light chain complementary determining region 2 (CDR-L2) having an amino acid sequence of SEQ ID NO:10, and a light chain complementary determining region 3 (CDR-L3) having an amino acid sequence of SEQ ID NO:11. In some embodiments, the EMCN-specific antigen binding domain has a heavy chain variable (VH) region and a light chain variable (VL) region, wherein: (1) VH comprises a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence of SEQ ID NO:3, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of SEQ ID NO:7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO:8, and (2) VL comprises a light chain complementary determining region 1 (CDR-L1) having an amino acid sequence of SEQ ID NO:9, a light chain complementary determining region 2 (CDR-L2) having an amino acid sequence of SEQ ID NO:10, and a light chain complementary determining region 3 (CDR-L3) having an amino acid sequence of SEQ ID NO:11. In some embodiments, the EMCN-specific antigen binding domain has a heavy chain variable (VH) region and a light chain variable (VL) region, wherein: (1) VH comprises a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence of SEQ ID NO:4, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of SEQ ID NO:7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO:8, and (2) VL comprises a light chain complementary determining region 1 (CDR-L1) having an amino acid sequence of SEQ ID NO:9, a light chain complementary determining region 2 (CDR-L2) having an amino acid sequence of SEQ ID NO:10, and a light chain complementary determining region 3 (CDR-L3) having an amino acid sequence of SEQ ID NO:11.In some embodiments, the EMCN-specific antigen binding domain has a heavy chain variable (VH) region and a light chain variable (VL) region, wherein: (1) VH comprises a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence of SEQ ID NO:5, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of SEQ ID NO:7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO:8, and (2) VL comprises a light chain complementary determining region 1 (CDR-L1) having an amino acid sequence of SEQ ID NO:9, a light chain complementary determining region 2 (CDR-L2) having an amino acid sequence of SEQ ID NO:10, and a light chain complementary determining region 3 (CDR-L3) having an amino acid sequence of SEQ ID NO:11.
[0115] In some embodiments, the EMCN-specific antigen binding domain has a variable heavy chain (VH) region and a variable light chain (VL) region, wherein the variable heavy chain region contains a VH complementary region 1 (CDRH1) having an amino acid sequence of SEQ ID NO: 1, a VH complementary region 2 (CDRH2) having an amino acid sequence of SEQ ID NO: 6, and a VH complementary region 3 (CDRH3) having an amino acid sequence of SEQ ID NO: 8; the variable light chain region contains a VL complementary region L (CDRL1) having an amino acid sequence of SEQ ID NO: 9, a VL complementary region 2 (CDRL2) having an amino acid sequence of SEQ ID NO: 10, and a VL complementary region 3 (CDRL3) having an amino acid sequence of SEQ ID NO: 11, and the antigen binding domain is humanized.
[0116] In some embodiments, the EMCN-specific antigen binding domain has a VH region comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, the EMCN-specific antigen binding domain has a VH region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12.
[0117] In some embodiments, the EMCN-specific antigen binding domain has a VH region comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, the EMCN-specific antigen binding domain has a VH region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 16.
[0118] In some embodiments, the EMCN-specific antigen binding domain has a VL region comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, the EMCN-specific antigen binding domain has a VL region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 20.
[0119] In some embodiments, the EMCN-specific antigen binding domain has (1) a VH region comprising the amino acid sequence of SEQ ID NO: 12, and (2) a VL region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 20, or a VL region comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, the EMCN-specific antigen binding domain has (1) a VH region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12, and (2) a VL region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 20, or a VL region comprising the amino acid sequence of SEQ ID NO: 20.
[0120] In some embodiments, the EMCN-specific antigen binding domain has (1) a VH region comprising the amino acid sequence of SEQ ID NO: 16, and (2) a VL region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 20, or a VL region comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, the EMCN-specific antigen binding domain has (1) a VH region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 16, and (2) a VL region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 20, or a VL region comprising the amino acid sequence of SEQ ID NO: 20.
[0121] In some embodiments, the EMCN-specific antigen binding domain has (1) a VL region comprising the amino acid sequence of SEQ ID NO:20, and (2) a VH region comprising the amino acid sequence of SEQ ID NO:12, or a VH region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:12. In some embodiments, the EMCN-specific antigen binding domain has a VL region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:20; and (2) a VH region comprising the amino acid sequence of SEQ ID NO:12, or a VH region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:12.
[0122] In some embodiments, the EMCN-specific antigen binding domain has (1) a VL region comprising the amino acid sequence of SEQ ID NO:20, and (2) a VH region comprising the amino acid sequence of SEQ ID NO:16, or a VH region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:16. In some embodiments, the EMCN-specific antigen binding domain has a VL region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:20; and (2) a VH region comprising the amino acid sequence of SEQ ID NO:16, or a VH region comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:16.
[0123] The EMCN-specific antigen binding domain may have any of the forms described herein, such as Fab, Fab', F(ab')2, Fv, scFv, linear antibodies, single domain antibodies (such as sdAb (VL or VH)), camelid VHH, and multispecific forms. In some embodiments, the EMCN-specific antigen binding domain has a F(ab) form. In some embodiments, the EMCN-specific antigen binding domain has a F(ab') form.
[0124] In some embodiments, the EMCN-specific antigen binding domain has a single chain variable fragment (scFv) format, including a scFv format with any of the peptide linkers described herein (e.g., see Table 2). In some embodiments, the EMCN-specific antigen binding domain has the structure VH-L-VL or VL-L-VH, wherein L is a peptide linker.
[0125] In some embodiments, the scFV has an amino acid sequence selected from SEQ ID NO:68, 70, 72, and 74.
[0126] In some embodiments, the EMCN-specific antigen binding domain is humanized.
[0127] The present disclosure also provides an EMCN-specific antigen-binding domain, which competes with a reference antibody or antigen-binding fragment thereof having a heavy chain variable (VH) region and a light chain variable (VL) region, wherein: (1) the VH comprises a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-5, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of SEQ ID NO: 7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO: 8, and (2) the VL comprises a light chain complementary determining region 1 (CDR-L1) having an amino acid sequence of SEQ ID NO: 9, a light chain complementary determining region 2 (CDR-L2) having an amino acid sequence of SEQ ID NO: 10, and a light chain complementary determining region 3 (CDR-L3) having an amino acid sequence of SEQ ID NO: 11.
[0128] The present disclosure also provides an EMCN-specific antigen-binding domain, which competes with a reference antibody or antigen-binding fragment thereof having a heavy chain variable (VH) region and a light chain variable (VL) region, wherein: (1) the VH comprises a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-5, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of SEQ ID NO: 7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO: 8, and (2) the VL comprises a light chain complementary determining region 1 (CDR-L1) having an amino acid sequence of SEQ ID NO: 9, a light chain complementary determining region 2 (CDR-L2) having an amino acid sequence of SEQ ID NO: 10, and a light chain complementary determining region 3 (CDR-L3) having an amino acid sequence of SEQ ID NO: 11.
[0129] In some embodiments, the EMCN-specific antigen binding domain binds to the same or substantially the same epitope (e.g., a different human EMCN epitope) as a reference antibody or antigen-binding fragment thereof having a heavy chain variable (VH) region and a light chain variable (VL) region, wherein: (1) the VH comprises a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-5, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of SEQ ID NO: 7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO: 8, and (2) the VL comprises a light chain complementary determining region 1 (CDR-L1) having an amino acid sequence of SEQ ID NO: 9, a light chain complementary determining region 2 (CDR-L2) having an amino acid sequence of SEQ ID NO: 10, and a light chain complementary determining region 3 (CDR-L3) having an amino acid sequence of SEQ ID NO: 11. In some embodiments, the EMCN-specific antigen binding domain binds to the same or substantially the same epitope (e.g., a different human EMCN epitope) as a reference antibody or antigen-binding fragment thereof having a heavy chain variable (VH) region and a light chain variable (VL) region, wherein: (1) the VH comprises a heavy chain complementary determining region 1 (CDR-H1) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-5, a heavy chain complementary determining region 2 (CDR-H2) having an amino acid sequence of SEQ ID NO: 7, and a heavy chain complementary determining region 3 (CDR-H3) having an amino acid sequence of SEQ ID NO: 8, and (2) the VL comprises a light chain complementary determining region 1 (CDR-L1) having an amino acid sequence of SEQ ID NO: 9, a light chain complementary determining region 2 (CDR-L2) having an amino acid sequence of SEQ ID NO: 10, and a light chain complementary determining region 3 (CDR-L3) having an amino acid sequence of SEQ ID NO: 11. In some embodiments, the EMCN-specific antigen binding domain binds to the same or substantially the same epitope (e.g., a different human EMCN epitope) as a reference antibody or antigen binding fragment thereof having a VH, wherein the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 12-19. In some embodiments, the EMCN-specific antigen binding domain binds to the same or substantially the same epitope (e.g., a different human EMCN epitope) as a reference antibody or antigen binding fragment thereof having a VL, wherein the VL comprises the amino acid sequence of SEQ ID NO: 20.
[0130] The present disclosure also provides chimeric proteins and nucleic acids encoding such chimeric proteins, the chimeric proteins comprising an EMCN-specific antigen binding domain having one or more of the amino acid sequences listed in Table 1. The chimeric protein may comprise any of the EMCN-specific antigen binding domains as described above.
[0131] Chimeric Antigen Receptor (CAR)
[0132] Certain aspects of the present disclosure relate to chimeric receptors, which have any one of the EMCN-specific antigen binding domains described herein and can specifically bind to EMCN proteins, EMCN-derived antigens or EMCN-derived epitopes. In some embodiments, the chimeric receptor is a chimeric antigen receptor (CAR). In general, CAR is a chimeric protein, including an antigen binding domain and a polypeptide molecule heterologous to the antigen binding domain (such as a peptide heterologous to an antibody that can be derived from the antigen binding domain). The polypeptide molecule heterologous to the antigen binding domain may include, but is not limited to, a transmembrane domain, one or more intracellular signaling domains, a hinge domain, a spacer, one or more peptide linkers, or a combination thereof.
[0133] In some embodiments, CAR is an engineered receptor that grafts the specificity of interest (e.g., EMCN) to or imparts immune effector cells. In certain embodiments, CAR can be used to graft the specificity of an antibody to an immunoreactive cell (such as a T cell). In some embodiments, CAR of the present disclosure includes an extracellular antigen binding domain (e.g., scFv) fused to a transmembrane domain and fused to one or more intracellular signaling domains.
[0134] In some embodiments, the chimeric antigen receptor is an activating chimeric antigen receptor (aCAR, and unless otherwise specified, is also generally referred to as CAR). In some embodiments, the binding of the chimeric antigen receptor to its cognate ligand is sufficient to induce the activation of immunoreactive cells. In some embodiments, the binding of the chimeric antigen receptor to its cognate ligand is sufficient to induce immunoreactive cell stimulation. In some embodiments, the activation of immunoreactive cells leads to the killing of target cells. In some embodiments, the activation of immunoreactive cells leads to the expression and / or secretion of cytokines or chemokines by immunoreactive cells. In some embodiments, the stimulation of immunoreactive cells leads to the expression and / or secretion of cytokines or chemokines by immunoreactive cells. In some embodiments, the stimulation of immunoreactive cells leads to the differentiation of immunoreactive cells. In some embodiments, the stimulation of immunoreactive cells induces the proliferation of immunoreactive cells. In some embodiments, the activation and / or stimulation of immunoreactive cells can be a combination of the above reactions.
[0135] The CARs of the present disclosure may be first generation, second generation, or third generation CARs. "First generation" CARs include a single intracellular signaling domain that is typically derived from a T cell receptor chain. "First generation" CARs typically have an intracellular signaling domain from the CD3-ζ (CD3ζ) chain, which is the primary transmitter of signals from endogenous TCRs. "First generation" CARs can provide de novo antigen recognition and enable CD4 + T cells and CD8 + T cells are activated by the CD3-ζ chain signaling domains in their single fusion molecules, and have nothing to do with HLA-mediated antigen presentation. "Second generation" CAR adds the second intracellular signaling domain from one of a variety of costimulatory molecules (e.g., CD28, 4-1BB, ICOS, OX40) to the cytoplasmic tail of CAR, so as to provide other signals to T cells. "Second generation" CAR provides costimulation (e.g., CD28 or 4-1BB) and activation (CD3-ζ). Preclinical studies have shown that "second generation" CAR can improve the anti-tumor activity of immunoreactive cells (such as T cells). "Third generation" CAR has multiple intracellular costimulatory signaling domains (e.g., CD28 and 4-1BB) and intracellular activation signaling domains (CD3-ζ).
[0136] In some embodiments, the chimeric antigen receptor is a chimeric inhibitory receptor (iCAR). In some embodiments, the one or more chimeric inhibitory receptors bind to an antigen expressed on a non-tumor cell, and the non-tumor cell is derived from a tissue selected from the group consisting of: brain, neuronal tissue, endocrine, bone, bone marrow, immune system, endothelial tissue, muscle, lung, liver, gallbladder, pancreas, gastrointestinal tract, kidney, bladder, male reproductive organ, female reproductive organ, fat, soft tissue and skin.
[0137] In some embodiments, a chimeric inhibitory receptor (e.g., an EMCN-specific chimeric inhibitory receptor) can be used, for example, together with one or more activating chimeric receptors (e.g., activating chimeric TCRs or CARs) expressed on cells of the present disclosure (e.g., immunoreactive cells), as a non-logic gate that controls, regulates, or inhibits one or more activities of one or more activating chimeric receptors. For example, if healthy cells express both antigens recognized by tumor-targeted chimeric receptors and antigens recognized by chimeric inhibitory receptors, immunoreactive cells expressing tumor antigens can bind to healthy cells. In this case, the inhibitory chimeric antigen will also bind to the cognate ligand on the healthy cell, and the inhibitory function of the chimeric inhibitory receptor will reduce, reduce, prevent, or inhibit the activation of immunoreactive cells by tumor-targeted chimeric receptors ("non-logic gating"). In some embodiments, the chimeric inhibitory receptor of the present disclosure can inhibit one or more activities of cells of the present disclosure (e.g., immunoreactive cells). In some embodiments, the immunoreactive cells may comprise one or more tumor-targeted chimeric receptors and one or more chimeric inhibitory receptors targeting antigens that are not expressed or generally believed to be expressed on tumors (e.g., EMCN). The combination of tumor-targeted chimeric receptors and chimeric inhibitory receptors in the same immunoreactive cell can be used to reduce on-target non-tumor toxicity.
[0138] In some embodiments, the extracellular antigen binding domain of the CAR of the present disclosure is about 2×10 -7 M or smaller, about 1×10 -7 M or smaller, about 9×10 -8 M or smaller, about 1×10 -8 M or smaller, about 9×10 -9 M or smaller, about 5×10 -9 M or smaller, about 4×10 -9 M or smaller, about 3×10 -9 M or smaller, about 2×10 -9 M or less or about 1×10 -9 M or less dissociation constant (K d ) binds to one or more antigens (e.g., EMCN). In some embodiments, K d The range is from about 2×10 - 7 M is about 1×10 -9 M.
[0139] The binding of the extracellular antigen binding domain of the CAR of the present disclosure can be measured by, for example, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), FACS analysis, bioassay (e.g., growth inhibition), biolayer interferometry (e.g., ), surface plasmon resonance (SPR) techniques (e.g., ) or Western blot assay. Each of these assays is usually detected by using a labeling agent (e.g., antibody or scFv) specific to the relevant complex to detect the presence of a protein-antibody complex of particular interest. For example, scFv can be radioactively labeled and used in RIA assays. Radioisotopes can be detected by means such as using a γ counter or scintillation counter or by automatic radiography. In certain embodiments, the extracellular antigen-binding domain of CAR is labeled with a fluorescent marker. Non-limiting examples of fluorescent markers include green fluorescent protein (GFP), blue fluorescent protein (e.g., EBFP, EBFP2, Azurite and mKalamal), cyan fluorescent protein (e.g., ECFP, Cerulean and CyPet) and yellow fluorescent protein (e.g., YFP, Citrine, Venus and YPet). In certain embodiments, the extracellular antigen-binding domain of CAR is labeled with a second antibody specific to the extracellular antigen-binding domain, and wherein the second antibody is labeled (e.g., radiolabeled or labeled with a fluorescent marker).
[0140] In some embodiments, the CAR of the present disclosure includes an extracellular antigen binding domain, a transmembrane domain, and one or more intracellular signaling domains that bind to EMCN (e.g., EMCN protein, EMCN-derived antigen, or EMCN-derived epitope). In some embodiments, the extracellular antigen binding domain includes scFv. In some embodiments, the extracellular antigen binding domain includes a Fab fragment that may be cross-linked. In certain embodiments, the extracellular binding domain is a F(ab)2 fragment.
[0141] Extracellular antigen binding domain
[0142] The extracellular antigen binding domain of the CAR disclosed herein specifically binds to EMCN (e.g., EMCN protein, EMCN-derived antigen or EMCN-derived epitope). In certain embodiments, the extracellular antigen binding domain binds to EMCN expressed on hematopoietic stem cells. In certain embodiments, the extracellular antigen binding domain binds to EMCN expressed on cells generally considered to be healthy (such as healthy HSCP). In some embodiments, EMCN is human EMCN.
[0143] The antigen binding domain of the present disclosure may comprise any domain that binds to an antigen, including but not limited to monoclonal antibodies, polyclonal antibodies, recombinant antibodies, bispecific antibodies, conjugated antibodies, human antibodies, humanized antibodies, and functional fragments thereof, including but not limited to single domain antibodies (sdAb) (such as heavy chain variable domains (VH), light chain variable domains (VL), and variable domains (VHH) of camelid-derived nanobodies), and alternative scaffolds known in the art that serve as antigen binding domains (such as recombinant fibronectin domains, T cell receptors (TCR), recombinant TCRs with enhanced affinity, or fragments thereof, e.g., single chain TCRs), etc. In some cases, it is advantageous for the antigen binding domain to be derived from the same species in which the CAR is ultimately used.
[0144] In some embodiments, the extracellular antigen binding domain comprises an antibody. In certain embodiments, the antibody is a human antibody. In certain embodiments, the antibody is a chimeric antibody. In some embodiments, the extracellular antigen binding domain comprises an antigen-binding fragment of an antibody.
[0145] In some embodiments, the extracellular antigen binding domain comprises a F(ab) fragment. In certain embodiments, the extracellular antigen binding domain comprises a F(ab') fragment.
[0146] In some embodiments, the extracellular antigen binding domain includes scFv. In some embodiments, the extracellular antigen binding domain includes two single-chain variable fragments (scFv). In some embodiments, each of the two scFvs binds to different epitopes on the same antigen. In some embodiments, the extracellular antigen binding domain includes a first scFv and a second scFv. In some embodiments, the first scFv and the second scFv bind to different epitopes on the same antigen. In certain embodiments, scFv is a mammalian scFv. In certain embodiments, scFv is a chimeric scFv. In certain embodiments, the scFv comprises a heavy chain variable domain (VH) and a light chain variable domain (VL).
[0147] In certain embodiments, the VH and the VL are separated by a peptide linker. In certain embodiments, the peptide linker comprises any one of the amino acid sequences shown in Table 2. In certain embodiments, scFv includes structure VH-L-VL or VL-L-VH, wherein VH is a heavy chain variable domain, L is a peptide linker, and VL is a light chain variable domain. In some embodiments, one or more scFvs each include structure VH-L-VL or VL-L-VH, wherein VH is a heavy chain variable domain, L is a peptide linker, and VL is a light chain variable domain. When two or more scFvs are connected together, each scFv can be connected to the next scFv by a peptide connection. In some embodiments, one or more scFvs are each separated by a peptide linker.
[0148] Table 2. Peptide linkers
[0149]
[0150]
[0151] In some embodiments, the immune effector cell comprises a first chimeric receptor and a second chimeric receptor. The antigen binding domain of the first chimeric receptor and the antigen binding domain of the second chimeric receptor can be suitable antigen binding domains as described herein or known in the art. For example, the first antigen binding domain or the second antigen binding domain can be one or more antibodies, antigen binding fragments of antibodies, F (ab) fragments, F (ab') fragments, single chain variable fragments (scFv) or single domain antibodies (sdAb). In some embodiments, the antigen binding domain of the first chimeric receptor and / or the second chimeric receptor includes two single chain variable fragments (scFv). In some embodiments, each of the two scFvs is bound to different epitopes on the same antigen. In some embodiments, the antigen binding domain of the first chimeric receptor can be specific to EMCN, and the chimeric receptor can be specific to a second different antigen (such as a cancer antigen (e.g., an antigen expressed on bone marrow cells (such as AML cells))).
[0152] In some embodiments, the extracellular antigen binding domain comprises a single domain antibody (sdAb). In certain embodiments, the sdAb is a humanized sdAb. In certain embodiments, the sdAb is a chimeric sdAb.
[0153] In some embodiments, the CAR of the present disclosure may include two or more antigen binding domains, three or more antigen binding domains, four or more antigen binding domains, five or more antigen binding domains, six or more antigen binding domains, seven or more antigen binding domains, eight or more antigen binding domains, nine or more antigen binding domains, or ten or more antigen binding domains. In some embodiments, the two or more antigen binding domains each bind to the same antigen. In some embodiments, the two or more antigen binding domains each bind to different epitopes of the same antigen. In some embodiments, the two or more antigen binding domains each bind to different antigens.
[0154] In some embodiments, CAR includes two antigen binding domains. In some embodiments, the two antigen binding domains are connected to each other via a flexible joint. In some embodiments, the two antigen binding domains can each be independently selected from antibodies, antigen binding fragments of antibodies, scFv, sdAb, recombinant fibronectin domains, T cell receptors (TCR), recombinant TCRs and single-chain TCRs with increased affinity. In some embodiments, the CAR including two antigen binding domains is a bispecific CAR or a tandem CAR (tanCAR).
[0155] In certain embodiments, the bispecific CAR or tanCAR include an antigen binding domain including a bispecific antibody or antibody fragment (e.g., scFv). In some embodiments, in each antibody or antibody fragment (e.g., scFv) of a bispecific antibody molecule, VH can be upstream or downstream of VL. In some embodiments, an upstream antibody or antibody fragment (e.g., scFv) is arranged with its VH (VH1), and its VH is upstream of its VL (VL1), and a downstream antibody or antibody fragment (e.g., scFv) is arranged with its VL (VL2), and its VL is upstream of its VH (VH2), so that the entire bispecific antibody molecule has an arrangement mode VH1-VL1-VL2-VH2. In other embodiments, the upstream antibody or antibody fragment (e.g., scFv) is arranged with its VL (VL1), and its VL is upstream of its VH (VH1), and the downstream antibody or antibody fragment (e.g., scFv) is arranged with its VH (VH2), and its VH is upstream of its VL (VL2), so that the entire bispecific antibody molecule has an arrangement mode VL1VH1-VL2-VH2. In some embodiments, if the construct is arranged as VH1-VL1-VL2-VH2, the joint is arranged between the two antibodies or antibody fragments (e.g., scFv), for example, between VL1 and VL2, or if the construct is arranged as VL1-VH1-VH2-VL2, the joint is arranged between VH1 and VH2. The joint can be a joint as described herein, for example, a (Gly4-Ser)n joint, wherein n is 1, 2, 3, 4, 5 or 6. In general, the length of the joint between the two scFvs should be sufficient to avoid mismatching between the domains of the two scFvs. In some embodiments, the joint is arranged between the VL and VH of the first scFv. In some embodiments, the joint is arranged between the VL and VH of the second scFv. In a construct with multiple joints, any two or more of the joints may be the same or different. Therefore, in some embodiments, bispecific CAR or tanCAR comprises VL, VH, and may further comprise one or more joints with an arrangement as described herein.
[0156] In some embodiments, the chimeric receptor comprises a bivalent CAR. In some embodiments, the bivalent CAR is an EMCN bivalent CAR. In some embodiments, the bivalent EMCN CAR comprises one or more of the anti-EMCN sequences shown in Table 1. In some embodiments, the ABDs of the bivalent EMCN CARs each comprise the same ABD.
[0157] In some embodiments, the chimeric receptor comprises a bicistronic chimeric antigen receptor. In some embodiments, the bicistronic chimeric antigen receptor comprises an EMCN CAR. In some embodiments, the bicistronic EMCN CAR comprises one or more of the anti-EMCN sequences shown in Table 1.
[0158] Transmembrane domain
[0159] In some embodiments, the transmembrane domain of CAR of the present disclosure (e.g., EMCN-specific CAR described herein) comprises a hydrophobic alpha helix that spans at least a portion of a cell membrane. It has been demonstrated that different transmembrane domains can produce different receptor stabilities. After antigen recognition, receptors aggregate and transmit signals to cells. In some embodiments, the transmembrane domain of CAR of the present disclosure may include CD8 polypeptides, CD28 polypeptides, CD3-ζ polypeptides, CD4 polypeptides, 4-1BB polypeptides, OX40 polypeptides, ICOS polypeptides, CTLA-4 polypeptides, PD-1 polypeptides, LAG-3 polypeptides, 2B4 polypeptides, BTLA polypeptides, LIR-1 (LILRB1) polypeptide transmembrane domains, or may be synthetic peptides or any combination thereof.
[0160] In some embodiments, the transmembrane domain is derived from a CD8 polypeptide. Any suitable CD8 polypeptide can be used. Exemplary CD8 polypeptides include, but are not limited to, NCBI reference numbers NP_001139345 and AAA92533.1. In some embodiments, the transmembrane domain is derived from a CD28 polypeptide. Any suitable CD28 polypeptide can be used. Exemplary CD28 polypeptides include, but are not limited to, NCBI reference numbers NP_006130.1 and NP_031668.3. In some embodiments, the transmembrane domain is derived from a CD3-ζ polypeptide. Any suitable CD3-ζ polypeptide can be used. Exemplary CD3-ζ polypeptides include, but are not limited to, NCBI reference numbers NP_932170.1 and NP_001106862.1. In some embodiments, the transmembrane domain is derived from a CD4 polypeptide. Any suitable CD4 polypeptide can be used. Exemplary CD4 polypeptides include, but are not limited to, NCBI reference numbers NP_000607.1 and NP_038516.1. In some embodiments, the transmembrane domain is derived from a 4-1BB polypeptide. Any suitable 4-1BB polypeptide can be used. Exemplary 4-1BB polypeptides include, but are not limited to, NCBI reference numbers NP_001552.2 and NP_001070977.1. In some embodiments, the transmembrane domain is derived from an OX40 polypeptide. Any suitable OX40 polypeptide can be used. Exemplary OX40 polypeptides include, but are not limited to, NCBI reference numbers NP_003318.1 and NP_035789.1. In some embodiments, the transmembrane domain is derived from an ICOS polypeptide. Any suitable ICOS polypeptide can be used. Exemplary ICOS polypeptides include, but are not limited to, NCBI reference numbers NP_036224 and NP_059508. In some embodiments, the transmembrane domain is derived from a CTLA-4 polypeptide. Any suitable CTLA-4 polypeptide can be used. Exemplary CTLA-4 polypeptides include, but are not limited to, NCBI reference numbers NP_005205.2 and NP_033973.2. In some embodiments, the transmembrane domain is derived from a PD-1 polypeptide. Any suitable PD-1 polypeptide may be used. Exemplary PD-1 polypeptides include, but are not limited to, NCBI reference numbers NP_005009 and NP_032824. In some embodiments, the transmembrane domain is derived from a LAG-3 polypeptide. Any suitable LAG-3 polypeptide may be used. Exemplary LAG-3 polypeptides include, but are not limited to, NCBI reference numbers NP_002277.4 and NP_032505.1. In some embodiments, the transmembrane domain is derived from a 2B4 polypeptide. Any suitable 2B4 polypeptide may be used. Exemplary 2B4 polypeptides include, but are not limited to, NCBI reference numbers NP_057466.1 and NP_061199.2. In some embodiments, the transmembrane domain is derived from a BTLA polypeptide.Any suitable BTLA polypeptide may be used. Exemplary BTLA polypeptides include, but are not limited to, NCBI reference numbers NP_861445.4 and NP_001032808.2. Any suitable LIR-1 (LILRB1) polypeptide may be used. Exemplary LIR-1 (LILRB1) polypeptides include, but are not limited to, NCBI reference numbers NP_001075106.2 and NP_001075107.2.
[0161] In some embodiments, the transmembrane domain comprises a polypeptide having a transmembrane domain and a transmembrane domain ... 5205.2, NP_033973.2, NP_005009, NP_032824, NP_002277.4, NP_032505.1, NP_057466.1, NP_061199.2, NP_861445.4 or NP_001032808.2, or a fragment thereof at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% homologous to an amino acid sequence. In some embodiments, homology can be determined using standard software such as BLAST or FASTA. In some embodiments, the polypeptide can include one conservative amino acid substitution, up to two conservative amino acid substitutions, or up to three conservative amino acid substitutions. In some embodiments, the polypeptide may have a NCBI reference number of NP_001139345, AAA92533.1, NP_006130.1, NP_031668.3, NP_932170.1, NP_001106862.1, NP_000607.1, NP_038516.1, NP_001552.2, NP_001070977.1, NP_003318.1, NP_035789.1, NP_036224, NP_059508, NP_005205.2, NP_033973.2, NP_005009, NP _032824, NP_002277.4, NP_032505.1, NP_057466.1, NP_061199.2, NP_861445.4 or NP_001032808.2, which has a length of at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230 or at least 240 amino acids.
[0162] Other examples of suitable polypeptides from which a transmembrane domain can be derived include, but are not limited to, the transmembrane region of the α, β or ζ chain of the T cell receptor, CD27, CD3ε, CD45, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, CD2, CD27, LFA-1 (CD11a, CD18), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2Rβ, IL2Rγ, IL7Rα, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGA C EACAM1, CRTAM, Ly9(CD229), CD160(BY55), PSGL1, CD100(SEMA4D), SLAMF6(NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG / Cbp, NKG2D and NG2C.
[0163] In some embodiments, the transmembrane domain comprises the sequence IYIWAPLAGTCGVLLLSLVIT (SEQ ID NO: 38). In some embodiments, the transmembrane domain comprises the sequence IYIWAPLAGTCGVLLLSLVITLYCNHR (SEQ ID NO: 39). In some embodiments, the transmembrane domain comprises the sequence IYIWAPLAGTCGVLLLSLVITLYCNHRN (SEQ ID NO: 40).
[0164] Spacer
[0165] In some embodiments, CAR of the present disclosure (e.g., EMCN-specific CAR described herein) may additionally include a spacer, which connects the extracellular antigen-binding domain to a transmembrane domain. The flexibility of the spacer may be sufficient to allow the antigen-binding domain to be oriented in different directions to promote antigen recognition. In some embodiments, the spacer may be a hinge from a human protein. For example, the hinge may be a human Ig (immunoglobulin) hinge, including but not limited to an IgG4 hinge, an IgG2 hinge, a CD8a hinge, or an IgD hinge. In some embodiments, the spacer may include an IgG4 hinge, an IgG2 hinge, an IgD hinge, a CD28 hinge, a KIR2DS2 hinge, an LNGFR hinge, or an extracellular joint of a PDGFR-β cell. In some embodiments, the spacer is positioned between the antigen-binding domain and the transmembrane domain. In some embodiments, the spacer may comprise any one of the amino acid sequences listed in Table 3, or an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of the amino acid sequences listed in Table 3. In some embodiments, the nucleic acid encoding any one of the spacers of the present disclosure may comprise any one of the nucleic acid sequences listed in Table 4, or a nucleic acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of the nucleic acid sequences listed in Table 4.
[0166] Table 3. Interval amino acid sequences
[0167]
[0168] Table 4. Interval nucleic acid sequences
[0169]
[0170]
[0171] In some embodiments, the spacer includes the sequence shown in SEQ ID NO:41. In some embodiments, the spacer includes the sequence shown in SEQ ID NO:42. In some embodiments, the spacer includes the sequence shown in SEQ ID NO:43. In some embodiments, the spacer includes the sequence shown in SEQ ID NO:44. In some embodiments, the spacer includes the sequence shown in SEQ ID NO:45. In some embodiments, the spacer includes the sequence shown in SEQ ID NO:46. In some embodiments, the spacer includes the sequence shown in SEQ ID NO:47. In some embodiments, the spacer includes the sequence shown in SEQ ID NO:48. In some embodiments, the spacer includes the sequence shown in SEQ ID NO:49. In some embodiments, the spacer includes the sequence shown in SEQ ID NO:50. In some embodiments, the spacer includes the sequence shown in SEQ ID NO:51. In some embodiments, the spacer includes the sequence shown in SEQ ID NO:52.
[0172] In some embodiments, the CAR of the present disclosure may further include a short oligopeptide or polypeptide linker having a length between 2 and 10 amino acid residues, and a linker may be formed between the transmembrane domain and the cytoplasmic region of the CAR. A non-limiting example of a suitable linker is a glycine-serine doublet. In some embodiments, the linker includes the amino acid sequence of GGCKJSGGCKJS (SEQ ID NO: 62).
[0173] In some aspects, the transmembrane domain also comprises at least a portion of the extracellular domain of the same protein.
[0174] Intracellular signaling domain
[0175] In some embodiments, CAR of the present disclosure (e.g., EMCN-specific CAR described herein) comprises one or more cytoplasmic domains or cytoplasmic regions. The cytoplasmic domain or cytoplasmic region of CAR may include an intracellular signaling domain.
[0176] Examples of suitable intracellular signaling domains that can be used in the CARs of the present disclosure include, but are not limited to, cytoplasmic sequences of T cell receptors (TCRs) and co-receptors that act synergistically to regulate signal transduction following antigen receptor engagement, as well as any derivatives or variants of these sequences and any recombinant sequences with the same functional capabilities.
[0177] Without wishing to be bound by theory, it is believed that the signal generated by TCR alone is insufficient to fully activate T cells, and therefore secondary and / or co-stimulatory signals are generally required to fully activate. Therefore, T cell activation can be mediated by two different categories of cytoplasmic signaling sequences, i.e., those sequences that initiate antigen-dependent primary activation through TCR (primary intracellular signaling domain), and those sequences that act in an antigen-independent manner to provide secondary or co-stimulatory signals (secondary cytoplasmic domains, e.g., co-stimulatory domains). In addition, T cell signaling and function (e.g., activation signaling cascades) can be negatively regulated by inhibitory receptors present in T cells through intracellular inhibitory co-signaling domains.
[0178] In some embodiments, the intracellular signaling domain of the CAR of the present disclosure may include an inhibitory intracellular signaling domain. Examples of inhibitory intracellular domains that can be used include PD-1, CTLA4, TIGIT, BTLA and LIR-1 (LILRB1), TIM3, KIR3DL1, NKG2A, LAG3, SLAP1, SLAP2, Dok-1, Dok-2, LAIR1, GRB-2, CD200R, SIRPα, HAVR, GITR, PD-L1, KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL2, CD94, KLRG-1, CEACAM1, LIR2, LIR3, LIR5, SIGLEC-2 and SIGLEC-10. In some embodiments, the inhibitory intracellular signaling domain includes one or more intracellular inhibitory co-signaling domains. In some embodiments, one or more intracellular inhibitory co-signaling domains are connected to other domains (e.g., transmembrane domains) by a peptide linker (e.g., see Table 2) or a spacer or hinge sequence (e.g., see Table 3). In some embodiments, when two or more intracellular inhibitory co-signaling domains are present, the two or more intracellular inhibitory co-signaling domains may be connected by a peptide linker (e.g., see Table 2) or a spacer or hinge sequence (e.g., see Table 3). In some embodiments, the intracellular inhibitory co-signaling domain is an inhibitory domain. In some embodiments, the one or more intracellular inhibitory co-signaling domains of the chimeric protein include one or more ITIM-containing proteins or fragments thereof. ITIM is a conserved amino acid sequence present in the cytoplasmic tail of many inhibitory immune receptors. Examples of ITIM-containing proteins include PD-1, TIGIT, BTLA and LIR-1 (LILRB1), TIM3, KIR3DL1, NKG2A, LAG3, LAIR1, SIRPα, KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL2, CD94, KLRG-1, CEACAM1, LIR2, LIR3, LIR5, SIGLEC-2 and SIGLEC-10. In some embodiments, one or more intracellular inhibitory co-signaling domains comprise one or more non-ITIM scaffold proteins or fragments thereof. In some embodiments, one or more non-ITIM scaffold proteins or fragments thereof are selected from GRB-2, Dok-1, Dok-2, SLAP, LAG3, HAVR, GITR and PD-L1. The inhibitory intracellular signaling domain may further comprise an enzyme inhibitory domain. In some embodiments, the enzyme inhibitory domain comprises an enzymatic catalytic domain.In some embodiments, the enzymatic catalytic domain is derived from an enzyme selected from the group consisting of CSK, SHP-1, PTEN, CD45, CD148, PTP-MEG1, PTP-PEST, c-CBL, CBL-b, PTPN22, LAR, PTPH1, SHIP-1, and RasGAP. Examples of enzymatic regulation of signaling are described in Pavel Otáhal et al. (Biochim Biophys Acta. 2011 Feb;1813(2):367-76), Kosugi A. et al. (Involvement of SHP-1 tyrosine phosphatase in TCR-mediated signaling pathways in lipid rafts, Immunity, 2001 Jun;14(6):669-80), and Stanford et al. (Regulation of TCR signaling by tyrosine phosphatases: from immune homeostasis to autoimmunity). The present invention relates to the regulation of autoimmunity, Immunity, Sep 2012; 137(1): 1-19, each of which is incorporated herein by reference for all purposes.
[0179] In some embodiments, the intracellular signaling domain of the CAR of the present disclosure may include a primary signaling domain, which regulates the primary activation of the TCR complex in a stimulating manner or an inhibitory manner. The primary intracellular signaling domain that plays a role in a stimulating manner may contain a signaling motif, which is called an activation motif (ITAM) based on immunoreceptor tyrosine. Examples of suitable primary intracellular signaling domains containing ITAMs that can be used for CAR of the present disclosure include but are not limited to CD3-ζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD5, CD22, CD79a, CD79b, CD278 (also referred to as "ICOS"), FcεRI, DAP10, DAP12 and CD66d.
[0180] In some embodiments, the CAR of the present disclosure (e.g., EMCN-specific CAR described herein) comprises an intracellular signaling domain, such as a primary signaling domain of a CD3-ζ polypeptide. The CD3-ζ polypeptide of the present disclosure may have an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% homologous to a sequence or fragment thereof of NCBI reference number NP_932170 or NP_001106864.2. In some embodiments, the CD3-ζ polypeptide may include one conservative amino acid substitution, up to two conservative amino acid substitutions, or up to three conservative amino acid substitutions. In some embodiments, the polypeptide can have an amino acid sequence that is a contiguous portion of NCBI Reference No. NP_932170 or NP_001106864.2 that is at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, or at least 160, at least 170, or at least 180 amino acids in length.
[0181] In other embodiments, the primary signaling domain comprises a modified ITAM domain, such as a mutated ITAM domain having an altered (e.g., increased or decreased) activity compared to a native ITAM domain. In one embodiment, the primary signaling domain comprises a primary intracellular signaling domain containing a modified ITAM, such as a primary intracellular signaling domain containing an optimized and / or truncated ITAM. In one embodiment, the primary signaling domain comprises one, two, three, four or more ITAM motifs.
[0182] In some embodiments, the intracellular signaling domain of the CAR of the present disclosure may itself include a CD3-ζ signaling domain or it may be combined with any other desired intracellular signaling domain that can be used in the case of the CAR of the present disclosure. For example, the intracellular signaling domain of the CAR may include a CD3-ζ chain portion and a costimulatory signaling domain. The costimulatory signaling domain may refer to a portion of a CAR that includes an intracellular domain of a costimulatory molecule. The costimulatory molecules of the present disclosure are cell surface molecules other than antigen receptors or their ligands that may be required for the effective response of lymphocytes to antigens. Examples of suitable costimulatory molecules include, but are not limited to, CD97, CD2, ICOS, CD27, CD154, CD8, OX40, 4-1BB, CD28, ZAP40, CD30, GITR, HVEM, DAP10, DAP12, MyD88, 2B4, CD40, PD-1, lymphocyte function-associated antigen-1 (LFA-1), CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83, MHC Class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activation molecules (SLAM proteins), activating NK cell receptors, BTLA, Toll ligand receptors, CDS, ICAM-1, (CD11a / CD18), BAFFR, KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, ITGAM, CD11b, ITGA X, CD11c, ITGB1, CD29, ITGB2, CD18, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM1, CRTAM, Ly9(CD229), CD160 (BY55), PSGL1, CD100(SEMA4D), CD69, SLAMF6(NTB-A, Ly108), SLAM(SLAMF1, CD150, IPO-3), BLAME(SLAMF8), SELPLG(CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, etc.
[0183] In some embodiments, the intracellular signaling sequences in the cytoplasmic portion of the CAR of the present disclosure can be connected to each other in a random or specified order. In some embodiments, for example, a short oligopeptide or polypeptide linker with a length between 2 amino acids and 10 amino acids (e.g., 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, or 10 amino acids) can form a bond between intracellular signaling sequences. In one embodiment, a glycine-serine doublet can be used as a suitable joint. In one embodiment, a single amino acid, such as alanine or glycine, can be used as a suitable joint.
[0184] In some embodiments, the intracellular signaling domain includes two or more costimulatory signaling domains, for example, two costimulatory signaling domains, three costimulatory signaling domains, four costimulatory signaling domains, five costimulatory signaling domains, six costimulatory signaling domains, seven costimulatory signaling domains, eight costimulatory signaling domains, nine costimulatory signaling domains, 10 costimulatory signaling domains or more costimulatory signaling domains. In one embodiment, the intracellular signaling domain includes two costimulatory signaling domains. In some embodiments, two or more costimulatory signaling domains are separated by a linker of the present disclosure (e.g., any one of the linkers described in Table 2). In one embodiment, the linker is a glycine residue. In another embodiment, the linker is an alanine residue.
[0185] In some embodiments, the cells of the present disclosure express a CAR comprising an antigen binding domain that binds EMCN, a transmembrane domain of the present disclosure, a primary signaling domain, and one or more co-stimulatory signaling domains.
[0186] In some embodiments, the cells of the present disclosure express iCAR, the iCAR comprising an antigen binding domain that binds to EMCN (e.g., an EMCN-specific antigen binding domain having one or more of the amino acid sequences listed in Table 1), a transmembrane domain of the present disclosure, and one or more intracellular inhibitory co-signaling domains. In some embodiments, the cells of the present disclosure express CAR, the CAR comprising an antigen binding domain that binds to EMCN (e.g., an EMCN-specific antigen binding domain having one or more of the amino acid sequences listed in Table 1), a transmembrane domain of the present disclosure, a primary signaling domain, and one or more costimulatory signaling domains. In some embodiments, the cells of the present disclosure express CAR, the CAR comprising an antigen binding domain that binds to EMCN (e.g., an EMCN-specific antigen binding domain having one or more of the amino acid sequences listed in Table 1), a transmembrane domain of the present disclosure, a hinge positioned between the antigen binding domain and the transmembrane domain, a primary signaling domain, and one or more costimulatory signaling domains.
[0187] In some embodiments, the transmembrane domain is derived from the same protein as one of the one or more intracellular signaling domains. In some embodiments, CAR is an inhibitory CAR and comprises a transmembrane domain and at least one intracellular inhibitory co-signaling domain, each intracellular inhibitory co-signaling domain is derived from a protein selected from the group consisting of PD-1, CTLA4, TIGIT, BTLA and LIR1 (LILRB1), TIM3, KIR3DL1, NKG2A, LAG3, SLAP1, SLAP2, Dok-1, Dok-2, LAIR1, GRB-2, CD200R, SIRPα, HAVR, GITR, PD-L1, KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL2, CD94, KLRG-1, CEACAM1, LIR2, LIR3, LIR5, SIGLEC-2, and SIGLEC-10.
[0188] In some embodiments, the transmembrane domain is derived from a first protein and the one or more intracellular signaling domains are derived from a second protein that is different from the first protein.
[0189] Natural Killer Cell Receptor (NKR) CAR
[0190] In some embodiments, the CAR of the present disclosure (e.g., EMCN-specific CAR described herein) comprises one or more components of a natural killer cell receptor (NKR), thereby forming a NKR-CAR. The NKR component can be a transmembrane domain, hinge domain, or cytoplasmic domain from any suitable natural killer cell receptor, including but not limited to killer cell immunoglobulin-like receptors (KIRs), such as KIR2DL1, KIR2DL2 / L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, DIR2DS5, KIR3DL1 / S1, KIR3DL2, KIR3DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, DIR2DS5, KIR3DL1 / S1, KIR3DL2, KIR3DL4, KIR3 ...4, KIR3DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, DIR2DS5, KIR3DL1 / S1, IR3DL3, KIR2DP1 and KIRSDPI; natural cytotoxicity receptors (NCRs), such as NKp30, NKp44, NKp46; signaling lymphocyte activation molecule (SLAM) family of immune cell receptors, such as CD48, CD229, 2B4, CD84, NTB-A, CRACC, BLAME and CD2F-10; Fc receptors (FcRs), such as CD16 and CD64; and Ly49 receptors, such as LY49A and LY49C. In some embodiments, NKR-CAR can interact with an adapter molecule or an intracellular signaling domain (such as DAP12). Exemplary configurations and sequences of CARs including NKR components are described in International Patent Publication WO2014 / 145252 published on September 18, 2014.
[0191] Other chimeric receptor targets
[0192] Certain aspects of the present disclosure relate to chimeric receptors and nucleic acids encoding such chimeric receptors, which bind to antigens of interest other than EMCN. Certain aspects of the present disclosure relate to chimeric receptors and cells (such as immunoreactive cells) that have been genetically modified to express one or more of such chimeric receptors, which bind to antigens of interest other than EMCN, and methods for treating and / or preventing myeloid malignancies (such as AML) and other pathologies requiring antigen-specific immune responses using such receptors and cells. Malignant cells have developed a series of mechanisms to protect themselves from immune recognition and elimination. The present disclosure provides immunogenicity within the tumor microenvironment for the treatment of such malignant cells.
[0193] In some embodiments, the first chimeric receptor comprises an antigen binding domain that binds to EMCN (e.g., an EMCN-specific antigen binding domain having one or more of the amino acid sequences listed in Table 1), and the second chimeric receptor comprises an additional antigen binding domain that binds to a second antigen, such as a tumor-associated antigen (e.g., an AML-associated antigen). In some embodiments, the cell may express a first chimeric receptor specific for EMCN (e.g., a CAR comprising an EMCN-specific antigen binding domain having one or more of the amino acid sequences listed in Table 1) and a second chimeric receptor specific for a second antigen, such as a tumor-associated antigen (e.g., an AML-associated antigen). In some embodiments, the cell may express a first chimeric inhibitory receptor specific for EMCN (e.g., an inhibitory CAR comprising an EMCN-specific antigen binding domain having one or more of the amino acid sequences listed in Table A) and a second chimeric receptor specific for a second antigen, such as a tumor-associated antigen (e.g., an AML-associated antigen). For example, cells (e.g., immunoreactive cells) can be engineered to co-express or co-express iCAR and aCAR, the iCAR comprising an antigen binding domain binding to EMCN (e.g., an EMCN-specific antigen binding domain with one or more of the amino acid sequences listed in Table 1), the aCAR targeting tumor-associated antigens (e.g., AML-associated antigens). Suitable antibodies bound to antigens other than EMCN include any antibody, a natural or synthetic antibody, a full-length antibody or a fragment thereof, a monoclonal antibody, or a polyclonal antibody, which is sufficiently strong and specifically binds to a second antigen (e.g., a tumor-associated antigen (e.g., AML-associated antigen)). Examples of AML-associated antigens include FLT3, CD33, CD123, CLEC12A, CXCR4, and EphA3. In some embodiments, commercially available antibodies can be used to bind to a second antigen (e.g., a tumor-associated antigen (e.g., AML-associated antigen)). Those skilled in the art can easily obtain the CDR of commercially available antibodies using conventional sequencing techniques. In addition, those skilled in the art are able to construct nucleic acids encoding scFv and chimeric receptors (e.g., CAR and TCR) based on the CDRs of such commercially available antibodies.
[0194] T cell receptor (TCR)
[0195] Certain aspects of the present disclosure relate to a chimeric receptor that specifically binds to a second antigen, such as a tumor-associated antigen (e.g., an AML-associated antigen), and the chimeric receptor of the second antigen is an engineered T cell receptor (TCR). The TCR of the present disclosure is a disulfide-linked heterodimeric protein containing two variable chains that are expressed as part of a complex with an invariant CD3 chain molecule. TCRs are found on the surface of T cells and are responsible for recognizing antigens in the form of peptides that are bound to major histocompatibility complex (MHC) molecules. In certain embodiments, the TCR of the present disclosure includes an alpha chain encoded by TRA and a beta chain encoded by TRB. In certain embodiments, the TCR includes a gamma chain and a delta chain (encoded by TRG and TRD, respectively).
[0196] Each chain of a TCR consists of two extracellular domains: a variable (V) region and a constant (C) region. The constant region is proximal to the cell membrane, followed by a transmembrane region and a short cytoplasmic tail. The variable region binds to the peptide / MHC complex. Each variable region has three complementarity determining regions (CDRs).
[0197] In certain embodiments, TCR can form a receptor complex with three dimeric signaling modules CD3δ / ε, CD3γ / ε and CD247ζ / ζ or CD247ζ / η. When the TCR complex is engaged with its antigen and MHC (peptide / MHC), the T cell expressing the TCR complex is activated.
[0198] In some embodiments, the TCR of the present disclosure is a recombinant TCR. In certain embodiments, the TCR is a non-natural TCR. In certain embodiments, the TCR differs from naturally occurring TCR by at least one amino acid residue. In some embodiments, the TCR differs from naturally occurring TCR by at least 2 amino acid residues, at least 3 amino acid residues, at least 4 amino acid residues, at least 5 amino acid residues, at least 6 amino acid residues, at least 7 amino acid residues, at least 8 amino acid residues, at least 9 amino acid residues, at least 10 amino acid residues, at least 11 amino acid residues, at least 12 amino acid residues, at least 13 amino acid residues, at least 14 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at least 30 amino acid residues, at least 40 amino acid residues, at least 50 amino acid residues, at least 60 amino acid residues, at least 70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid residues, at least 100 amino acid residues or more amino acid residues. In certain embodiments, the TCR is modified by at least one amino acid residue relative to naturally occurring TCR. In certain embodiments, the TCR is modified by at least 2 amino acid residues, at least 3 amino acid residues, at least 4 amino acid residues, at least 5 amino acid residues, at least 6 amino acid residues, at least 7 amino acid residues, at least 8 amino acid residues, at least 9 amino acid residues, at least 10 amino acid residues, at least 11 amino acid residues, at least 12 amino acid residues, at least 13 amino acid residues, at least 14 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at least 30 amino acid residues, at least 40 amino acid residues, at least 50 amino acid residues, at least 60 amino acid residues, at least 70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid residues, at least 100 amino acid residues, or more amino acid residues relative to a naturally occurring TCR.
[0199] Chimeric TCR
[0200] In some embodiments, the TCR of the present disclosure comprises one or more antigen binding domains, which can be grafted to one or more constant domains of a TCR chain (e.g., a TCR α chain or a TCR β chain) to produce a chimeric TCR, which specifically binds to a second antigen of interest (e.g., a tumor-associated antigen (e.g., an AML-associated antigen)). Without wishing to be bound by theory, it is believed that the chimeric TCR can signal through the TCR complex when the antigen binds. For example, an antibody or antibody fragment (e.g., scFv) can be grafted to a constant domain, for example, at least a portion of an extracellular constant domain, a transmembrane domain, and a cytoplasmic domain of a TCR chain (such as a TCR α chain and / or a TCR β chain). For another example, the CDR of an antibody or antibody fragment can be grafted to a TCR α chain and / or a β chain to produce a chimeric TCR, which specifically binds to a second antigen (e.g., a tumor-associated antigen (e.g., an AML-associated antigen)). Such chimeric TCRs can be generated by methods known in the art (eg, Willemsen RA et al., Gene Therapy 2000;7:1369-1377; Zhang T et al., Cancer Gene Ther 2004 11:487-496; and Aggen et al., Gene Ther. 2012 Apr;19(4):365-74).
[0201] Immunoreactive cells
[0202] Certain aspects of the present disclosure relate to a cell, such as an immunoreactive cell, that has been genetically engineered to contain one or more chimeric receptors of the present disclosure or one or more nucleic acids encoding such chimeric receptors, and to methods of using such cells to treat myeloid malignancies (e.g., AML).
[0203] In some embodiments, the cell is a mammalian cell. In some embodiments, the mammalian cell is a primary cell. In some embodiments, the mammalian cell is a cell line. In some embodiments, the mammalian cell bone marrow cell, blood cell, skin cell, bone cell, muscle cell, neuronal cell, fat cell, liver cell or heart cell. In some embodiments, the cell is a stem cell. Exemplary stem cells include but are not limited to embryonic stem cells (ESC), induced pluripotent stem cells (iPSC), adult stem cells and tissue-specific stem cells, such as hematopoietic stem cells (blood stem cells), mesenchymal stem cells (MSC), neural stem cells, epithelial stem cells or skin stem cells. In some embodiments, the cell is a cell derived or differentiated from stem cells of the present disclosure. In some embodiments, the cell is an immune cell. The immune cells of the present disclosure can be separated or differentiated by stem cells of the present disclosure (e.g., by ESC or iPSC). Exemplary immune cells include, but are not limited to, T cells (e.g., helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, autologous killer T cells, αβT cells, and γδT cells), B cells, natural killer (NK) cells, dendritic cells, myeloid cells, macrophages, and monocytes. In some embodiments, the cells are neuronal cells. Neuronal cells of the present disclosure can be separated or differentiated from stem cells of the present disclosure (e.g., from ESC or iPSC). Exemplary neuronal cells include, but are not limited to, neural progenitor cells, neurons (e.g., sensory neurons, motor neurons, cholinergic neurons, GABAergic neurons, glutamatergic neurons, dopaminergic neurons, or serotonergic neurons), astrocytes, oligodendrocytes, and microglia.
[0204] In some embodiments, the cell is an immune response cell. The immune response cells of the present disclosure can be separated or differentiated by stem cells of the present disclosure (e.g., by ESC or iPSC). Exemplary immune response cells of the present disclosure include, but are not limited to, lymphoid lineage cells. Lymphoid lineages (including B cells, T cells, and natural killer (NK) cells) provide the production of antibodies, the regulation of the cellular immune system, the detection of foreign substances in the blood, the detection of host foreign cells, and the like. Examples of immune response cells of lymphoid lineages include, but are not limited to, T cells, natural killer (NK) cells, embryonic stem cells, pluripotent stem cells, and induced pluripotent stem cells (e.g., those stem cells from which lymphoid cells can be derived or differentiated). T cells can be lymphocytes that mature in the thymus and are primarily responsible for cell-mediated immunity. T cells are related to the adaptive immune system. In some embodiments, T cells of the present disclosure can be any type of T cell, including, but not limited to, T helper cells, cytotoxic T cells, memory T cells (including central memory T cells, stem cell-like memory T cells (or stem-like memory T cells)) and two types of effector memory T cells: for example, TEM Cells and T EMRA Cells, regulatory T cells (also called suppressor T cells), natural killer T cells, mucosal-associated invariant T cells, and γδ T cells. Cytotoxic T cells (CTLs or killer T cells) are a subset of T lymphocytes that are able to induce the death of infected somatic cells or tumor cells. The patient's own T cells can be genetically modified to target specific antigens by introducing one or more chimeric receptors (such as chimeric TCRs or CARs).
[0205] Natural Killer (NK) cells may be lymphocytes that function as part of cell-mediated immunity and during the innate immune response. NK cells do not require prior activation in order to perform their cytotoxic effects on target cells.
[0206] In some embodiments, the immune response cells of the present disclosure are T cells. The T cells of the present disclosure can be autologous, allogeneic, or derived in vitro from engineered progenitor cells or stem cells.
[0207] In some embodiments, the immune response cells of the present disclosure are universal T cells lacking TCR-αβ. In the art, methods for developing universal T cells are described in, for example, Valton et al., Molecular Therapy (2015); 23 9, 1507-1518, and Torikai et al., Blood 2012 119: 5697-5705.
[0208] In some embodiments, the immune response cells of the present disclosure are isolated immune response cells comprising one or more chimeric receptors of the present disclosure. In some embodiments, the immune response cells comprise one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more chimeric receptors of the present disclosure.
[0209] In some embodiments, the immune response cell is a T cell. In some embodiments, the immune response cell is a natural killer (NK) cell.
[0210] In some embodiments, immunoreactive cells express or can express immune receptors.Immunoreceptors are generally capable of inducing changes in signal transduction or protein expression in cells expressing immune receptors, thereby regulating immune responses (e.g., regulating, activating, starting, stimulating, increasing, preventing, weakening, inhibiting, reducing, reducing, hindering or suppressing immune responses) when bound to cognate ligands. For example, when CD3 chains are present in TCR / CAR clusters in response to ligand binding, signal transduction cascades mediated by activation motifs (ITAM) based on immune receptor tyrosine are generated. Specifically, in certain embodiments, when endogenous TCR, exogenous TCR, chimeric TCR or CAR (particularly activating CAR) bind to their respective antigens, immune synapses are formed, and the formation is included in the binding of receptors (e.g., CD4 or CD8, CD3γ / δ / ε / ζ, etc.) near the aggregation of many molecules. This aggregation of membrane-bound signal transduction molecules allows the ITAM motifs included in the CD3 chain to be phosphorylated, and then T cell activation pathways can be initiated and transcription factors (such as NF-κΒ and AP-1) can be finally activated. These transcription factors are able to induce global gene expression in T cells to increase IL-2 production, thereby promoting proliferation and expression of master regulatory T cell proteins, thereby initiating T cell-mediated immune responses such as cytokine production and / or T cell-mediated killing.
[0211] Cells expressing multiple chimeric receptors
[0212] In some embodiments, the cells of the present disclosure (e.g., immunoreactive cells) include two or more chimeric receptors of the present disclosure. In some embodiments, the cell includes two or more chimeric receptors, wherein one of the two or more chimeric receptors is a chimeric inhibitory receptor. In some embodiments, the cell includes three or more chimeric receptors, wherein at least one of the three or more chimeric receptors is a chimeric inhibitory receptor. In some embodiments, the cell includes four or more chimeric receptors, wherein at least one of the four or more chimeric receptors is a chimeric inhibitory receptor. In some embodiments, the cell includes five or more chimeric receptors, wherein at least one of the five or more chimeric receptors is a chimeric inhibitory receptor.
[0213] In some embodiments, each of two or more chimeric receptors comprises different antigen binding domains, for example, antigen binding domains that bind to the same antigen or different antigens. In some embodiments, each antigen bound by two or more chimeric receptors is expressed on the same cell, such as a bone marrow cell type (e.g., the same AML cell type). In some embodiments, each antigen bound by two or more chimeric receptors is an AML-associated antigen (e.g., FLT3, CD33, CD123, CLEC12A, CXCR4, EphA3, etc.).
[0214] In the embodiment that the cell (for example, immunoreactive cell) of the present disclosure expresses two or more different chimeric receptors, each antigen binding domain in different chimeric receptors can be designed so that antigen binding domains do not interact with each other.For example, the cell (for example, immunoreactive cell) of the present disclosure expresses the first chimeric receptor (for example, EMCN specific chimeric receptor) and the second chimeric receptor, and the cell can include the first chimeric receptor, and the first chimeric receptor includes the antigen binding domain that does not form association with the antigen binding domain of the second chimeric receptor.For example, the antigen binding domain of the first chimeric receptor can include an antibody fragment, such as scFv, and the antigen binding domain of the second chimeric receptor can include VHH.
[0215] Without wishing to be bound by theory, it is believed that in cells having multiple chimeric membrane-embedded receptors each comprising an antigen binding domain, interactions between the antigen binding domains of each receptor may be undesirable because such interactions may inhibit the ability of one or more of the antigen binding domains to bind to their cognate antigens. Therefore, in embodiments in which cells (e.g., immune response cells) of the present disclosure express two or more chimeric receptors, the chimeric receptors include antigen binding domains that minimize such inhibitory interactions. In one embodiment, the antigen binding domain of one chimeric receptor includes an scFv, and the antigen binding domain of the second chimeric receptor includes a single VH domain, such as a single VH domain of a camelid, shark, or lamprey, or a single VH domain derived from a human or mouse sequence.
[0216] In some embodiments, when present on the surface of a cell, the binding of the antigen binding domain of the first chimeric receptor to its cognate antigen (e.g., the binding of an EMCN-specific chimeric receptor to EMCN) is not substantially reduced by the presence of a second chimeric receptor. In some embodiments, the binding of the antigen binding domain of the first chimeric receptor to its cognate antigen in the presence of a second chimeric receptor is 85%, 90%, 95%, 96%, 97%, 98% or 99% of the binding of the antigen binding domain of the first chimeric receptor to its cognate antigen in the absence of a second chimeric receptor. In some embodiments, when present on the surface of a cell, the antigen binding domains of the first chimeric receptor and the second chimeric receptor are less associated with each other than when both are scFv antigen binding domains. In some embodiments, the degree to which the antigen binding domains of the first chimeric receptor and the second chimeric receptor are associated with each other is less than 85%, 90%, 95%, 96%, 97%, 98% or 99% less than when both are scFv antigen binding domains.
[0217] Chimeric inhibitory receptor
[0218] In some embodiments, cells (e.g., immunoreactive cells) of the present disclosure include one or more chimeric inhibitory receptors of the present disclosure. In some embodiments, each of the one or more chimeric inhibitory receptors includes an antigen binding domain that binds to antigens that are usually expressed on normal cells (e.g., cells that are generally considered healthy) but not tumor cells (such as AML cells). In some embodiments, the chimeric inhibitory receptor includes an antigen binding domain that binds to EMCN (e.g., an EMCN-specific antigen binding domain having one or more of the amino acid sequences listed in Table 1).
[0219] In some embodiments, the one or more chimeric inhibitory receptors bind to an antigen expressed on a non-tumor cell derived from a tissue selected from the group consisting of brain, neuronal tissue, endocrine, bone, bone marrow, immune system, endothelial tissue, muscle, lung, liver, gall bladder, pancreas, gastrointestinal tract, kidney, bladder, male reproductive organ, female reproductive organ, fat, soft tissue, and skin.
[0220] In some embodiments, a chimeric inhibitory receptor (e.g., an EMCN-specific chimeric inhibitory receptor) can be used, for example, together with one or more activating chimeric receptors (e.g., activating chimeric TCRs or CARs) expressed on a cell of the present disclosure (e.g., an immunoreactive cell) as a NOT logic gate that controls, regulates, or inhibits one or more activities of one or more activating chimeric receptors. In some embodiments, a chimeric inhibitory receptor of the present disclosure can inhibit one or more activities of a cell of the present disclosure (e.g., an immunoreactive cell).
[0221] In some embodiments, the cells of the present disclosure comprise one or more chimeric inhibitory receptors of the present disclosure and further comprise a tumor-targeted chimeric receptor that binds to one or more tumor-associated antigens. In some embodiments, the one or more tumor-associated antigens comprise AML-associated antigens. In some embodiments, the one or more tumor-associated antigens comprise CD33. In some embodiments, the one or more tumor-associated antigens comprise FLT3. In some embodiments, the one or more tumor-associated antigens comprise CD33 and FLT3.
[0222] Co-stimulatory ligand
[0223] In some embodiments, the cells of the present disclosure (e.g., immunoreactive cells) may additionally include one or more recombinant or exogenous costimulatory ligands. For example, cells may be further transduced with one or more costimulatory ligands so that cells co-express or are induced to co-express one or more chimeric receptors of the present disclosure (e.g., EMCN-specific CAR described herein) and one or more costimulatory ligands. It is not desirable to be bound by theory, but it is believed that the interaction between one or more chimeric receptors and one or more costimulatory ligands can provide non-antigen-specific signals important for the complete activation of cells. Examples of suitable costimulatory ligands include, but are not limited to, tumor necrosis factor (TNF) superfamily members and immunoglobulin (Ig) superfamily ligands. TNF is a cytokine involved in systemic inflammation and stimulates acute phase reactions. Its main function is to regulate immune cells. Members of the TNF superfamily have many common features. Most TNF superfamily members are synthesized as type II transmembrane proteins (extracellular C-terminals) containing short cytoplasmic segments and relatively long extracellular regions. Examples of suitable TNF superfamily members include, but are not limited to, nerve growth factor (NGF), CD40L (CD40L) / CD 154, CD137L / 4-1BBL, TNF-a, CD134L / OX40L / CD252, CD27L / CD70, Fas ligand (FasL), CD30L / CD153, tumor necrosis factor β (TNFP) / lymphotoxin α (LTa), lymphotoxin β (LTP), CD257 / B cell activating factor (BAFF) / Blys / THANK / Tall-1, glucocorticoid-induced TNF receptor ligand (GITRL) and TNF-related apoptosis-inducing ligand (TRAIL), LIGHT (TNFSF 14). The immunoglobulin (Ig) superfamily is a large group of cell surface soluble proteins that participate in the recognition, binding or adhesion processes of cells. These proteins share structural features with immunoglobulins and have immunoglobulin domains (folds). Examples of suitable immunoglobulin superfamily ligands include, but are not limited to, CD80 and CD86 (both ligands of CD28), PD-L1 / (B7-H1), which is a ligand of PD-1. In certain embodiments, one or more co-stimulatory ligands are selected from 4-1BBL, CD80, CD86, CD70, OX40L, CD48, TNFRSF14, PD-L1, and combinations thereof.
[0224] Chemokine receptors
[0225] In some embodiments, the cell of the present disclosure (for example, immunoreactive cell) includes one or more chimeric receptors (for example, EMCN-specific CAR described herein) and may further include one or more chemokine receptors. For example, transgenic expression of chemokine receptor CCR2b or CXCR2 in cells (such as T cells) enhances transportation to solid tumors secreting CCL2 or secreting CXCL1 (Craddock et al., J Immunother. October 2010; 33 (8): 780-8 and Kershaw et al. Hum Gene Ther. November 1, 2002; 13 (16): 1971-80). It is not desirable to be bound by theory, it is believed that the chemokine receptors expressed on cells expressing chimeric receptors disclosed herein can recognize chemokines secreted by tumors and improve cell targeting to tumors, which can promote cell infiltration to tumors and enhance the anti-tumor efficacy of cells. The chemokine receptors disclosed herein may include naturally occurring chemokine receptors, recombinant chemokine receptors or their chemokine binding fragments. Examples of suitable chemokine receptors that can be expressed on the cells of the present disclosure include, but are not limited to, CXC chemokine receptors, such as CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, or CXCR7; CC chemokine receptors, such as CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, or CCR11; CX3C chemokine receptors, such as CX3CR1; XC chemokine receptors, such as XCR1; and chemokine binding fragments thereof. In some embodiments, the chemokine receptor to be expressed on the cell is selected based on the chemokines secreted by the tumor.
[0226] Chimeric receptor regulation
[0227] Some embodiments of the present disclosure relate to regulating one or more chimeric receptor activities (e.g., EMCN-specific CAR described herein) of cells expressing chimeric receptors of the present disclosure. There are several methods for regulating chimeric receptor activity. In some embodiments, adjustable chimeric receptors may be required, wherein one or more chimeric receptor activities can be controlled to optimize the safety and / or efficacy of chimeric receptor therapy. For example, using caspase fused to a dimerization domain to induce apoptosis (see, e.g., Di et al., "New England Journal of Medicine (N Engl. J. Med.)" November 3, 2011; 365 (18): 1673-1683) can be used as a safety switch in chimeric receptor therapy. In some embodiments, the cells expressing the chimeric receptor of the present disclosure may also express inducible caspase-9 (iCaspase-9) which induces caspase-9 activation and leads to cell apoptosis after administration of a dimerizing drug such as rimiducid (IUPAC name: [(1R)-3-(3,4-dimethoxyphenyl)-1-[3-[2-[2-[2-[3-[(1R)-3-(3,4-dimethoxyphenyl)-1-[(2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetyl]amino]ethylamino]-2-oxoethoxy]phenyl]propyl](2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate). In some embodiments, iCaspase-9 contains a binding domain including a chemical dimerization inducer (CID) that mediates dimerization in the presence of the CID, which results in inducible and selective depletion of cells expressing the chimeric receptor.
[0228] Alternatively, in some embodiments, the chimeric receptors of the present disclosure can be regulated by utilizing small molecules or antibodies that inactivate or otherwise inhibit the activity of the chimeric receptor. For example, antibodies can deplete cells expressing chimeric receptors by inducing antibody-dependent cell-mediated cytotoxicity (ADCC). In some embodiments, cells expressing chimeric receptors of the present disclosure can further express antigens recognized by molecules that can induce cell death by ADCC or complement-induced cell death. For example, cells expressing chimeric receptors of the present disclosure can further express receptors that can be targeted by antibodies or antibody fragments. Examples of suitable receptors that can be targeted by antibodies or antibody fragments include, but are not limited to, EpCAM, VEGFR, integrins (e.g., αvβ3, α4, α13 / 4β3, α4β7, α5β1, αvβ3, αv), TNF receptor superfamily members (e.g., TRAIL-R1 and TRAIL-R2), PDGF receptor, interferon receptor, folate receptor, GPNMB, ICAM-1, HLA-DR, CEA, CA-125, MUC1, TAG-72, IL-6 receptor, 5T4, GD2, GD3, CD2, CD3, CD4, CD 5. CD11, CD11a / LFA-1, CD15, CD18 / ITGB2, CD19, CD20, CD22, CD23 / IgE receptor, CD25, CD28, CD30, CD33, CD38, CD40, CD41, CD44, CD51, CD52, CD62L, CD74, CD80, CD125, CD147 / basigin, CD152 / CTLA-4, CD154 / CD40L, CD195 / CCR5, CD319 / SLAMF7 and EGFR, as well as truncated forms thereof.
[0229] In some embodiments, the chimeric receptor-expressing cells of the present disclosure may also express a truncated epidermal growth factor receptor (EGFR) that lacks signaling capability but retains an epitope recognized by a molecule capable of inducing ADCC (eg, WO 2011 / 056894).
[0230] In some embodiments, the cells expressing chimeric receptors of the present invention further comprise a highly expressed tight marker / suicide gene, which combines target epitopes from both CD32 antigen and CD20 antigen in cells expressing chimeric receptors, thereby binding anti-CD20 antibodies (e.g., rituximab), thereby causing selective depletion of cells expressing chimeric receptors by ADCC. Other methods for depleting cells expressing chimeric receptors of the present invention may include, but are not limited to, administering monoclonal anti-CD52 antibodies, which selectively bind to and target cells expressing chimeric receptors to be destroyed by inducing ADCC. In some embodiments, chimeric receptor ligands such as anti-atopic antibodies may be used to selectively target cells expressing chimeric receptors. In some embodiments, the anti-atopic antibodies may cause effector cell activity, such as ADCC or ADC activity. In some embodiments, the chimeric receptor ligand may be further coupled to an agent such as a toxin that induces cell killing. In some embodiments, the cells expressing chimeric receptors of the present invention may further express target proteins recognized by cell depletion agents of the present invention. In some embodiments, the target protein is CD20 and the cell depleting agent is an anti-CD20 antibody. In such embodiments, the cell depleting agent is administered once it is desired to reduce or eliminate cells expressing the chimeric receptor. In some embodiments, the cell depleting agent is an anti-CD52 antibody.
[0231] In some embodiments, the regulated chimeric receptor comprises a set of polypeptides, wherein the components of the chimeric receptor of the present disclosure are distributed on separate polypeptides or members. For example, the set of polypeptides can include a dimerization switch, which, in the presence of a dimerization molecule, can allow the polypeptides to couple to each other to form a functional chimeric receptor.
[0232] Nucleic acid constructs encoding EMCN-specific proteins
[0233] Certain aspects of the present disclosure relate to nucleic acids (e.g., isolated nucleic acids) encoding one or more EMCN-specific proteins of the present disclosure (e.g., EMCN-specific CARs described herein). In some embodiments, the nucleic acid is an RNA construct, such as a messenger RNA (mRNA) transcript or a modified RNA. In some embodiments, the nucleic acid is a DNA construct.
[0234] In some embodiments, the nucleic acid encoding of the present disclosure comprises one or more antigen binding domains (wherein each domain is bound to a target antigen (e.g., EMCN)), a transmembrane domain, and a chimeric receptor of one or more intracellular signaling domains. In some embodiments, the nucleic acid encodes a chimeric receptor comprising an antigen binding domain, a transmembrane domain, a primary signaling domain (e.g., a CD3-ζ domain), and one or more co-stimulatory signaling domains. In some embodiments, the nucleic acid further comprises a nucleotide sequence encoding a spacer. In some embodiments, the antigen binding domain is connected to the transmembrane domain via a spacer. In some embodiments, the spacer comprises a nucleic acid sequence selected from any nucleic acid sequence listed in Table 3. In some embodiments, the nucleic acid also comprises a nucleotide sequence encoding a leader sequence.
[0235] The nucleic acids disclosed herein can be obtained using any suitable recombinant method known in the art, including but not limited to by screening a library from cells expressing a gene of interest, by obtaining the gene of interest from a vector known to include the gene, or by isolating the gene of interest directly from cells and tissues containing the gene using standard techniques. Alternatively, the gene of interest can be produced synthetically.
[0236] In some embodiments, the nucleic acids of the present disclosure are contained in a vector. In some embodiments, the nucleic acids of the present disclosure are expressed in cells via a transposon, a CRISPR / Cas9 system, a TALEN, or a zinc finger nuclease.
[0237] In some embodiments, expression of a nucleic acid encoding a chimeric receptor of the present disclosure can be achieved by operably linking the nucleic acid to a promoter and incorporating the construct into an expression vector. Suitable vectors can replicate and integrate in eukaryotic cells. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters that can be used to regulate expression of the desired nucleic acid.
[0238] In some embodiments, the expression constructs of the present disclosure can also be used for nucleic acid immunization and gene therapy using standard gene delivery protocols (eg, US5399346, US5580859, and US5589466). In some embodiments, the vectors of the present disclosure are gene therapy vectors.
[0239] The nucleic acid of the present disclosure can be cloned into many types of vectors. For example, the nucleic acid can be cloned into a vector, including but not limited to a plasmid, a phage plasmid, a phage derivative, an animal virus or a cosmid. In some embodiments, the vector can be an expression vector, a replication vector, a probe generation vector or a sequencing vector.
[0240] In some embodiments, the plasmid vector comprises a transposon / transposase system to incorporate the disclosed nucleic acid into the host cell genome. Methods for expressing proteins in immune cells using transposon and transposase plasmid systems are generally described in Chicaybam L, Human Gene Therapy 2019 Apr; 30(4):511-522.doi:10.1089 / hum.2018.218; and P, Cytotherapy. April 2018; 20(4):507-520. doi:10.1016 / j.jcyt.2017.10.001, each of which is hereby incorporated by reference in its entirety. In some embodiments, the transposon system is a Sleeping Beauty transposon / translocase or a piggyBac transposon / translocase.
[0241] In some embodiments, the expression vector of the present disclosure can be provided to cells in the form of a viral vector. Suitable viral vector systems are well known in the art. For example, viral vectors can be derived from retroviruses, adenoviruses, adeno-associated viruses, herpes viruses and lentiviruses. In some embodiments, the vector of the present disclosure is a lentiviral vector. Slow viral vectors are suitable for long-term gene transfer because such vectors allow long-term stable integration of transgenics and reproduction in daughter cells. Slow viral vectors are also superior to vectors derived from tumor retroviruses (e.g., murine leukemia viruses) because slow viral vectors can transduce non-proliferating cells. In some embodiments, the vector of the present disclosure is an adenoviral vector (A5 / 35). In some embodiments, the vector of the present disclosure contains a replication origin, a promoter sequence, a suitable restriction endonuclease site and one or more selective markers (e.g., WO01 / 96584; WO01 / 29058; and US6326193) that are functional in at least one organism. Many virus-based systems have been developed for transferring genes into mammalian cells. The selected gene can be inserted into a vector and encapsulated in a retroviral particle using techniques known in the art. The recombinant virus can then be isolated and delivered to mammalian cells in vivo or in vitro. Many retroviral systems are known in the art.
[0242] In some embodiments, the carrier of the present disclosure comprises other promoter elements, such as the enhancer of the frequency of regulation transcription initiation.Enhancer is usually located in the region of 30bp to 110bp upstream of the start site, although it has been proved that many promoters also contain functional elements downstream of the start site.The interval between the promoter elements can be flexible, so that the promoter function is retained when the elements are reversed or moved relative to each other.For example, in thymidine kinase (tk) promoter, the interval between the promoter elements can be increased to 50bp, and then the activity begins to decline.Depending on the promoter, a single element can work together or independently to activate transcription.Exemplary promoters can include but are not limited to SFFV gene promoter, EFS gene promoter, CMV IE gene promoter, EF1a promoter, ubiquitin C promoter and phosphoglycerol kinase (PGK) promoter.
[0243] In some embodiments, the promoter capable of expressing the nucleic acids of the present disclosure in mammalian cells (such as the immune response cells of the present disclosure) is the EF1a promoter. The native EF1a promoter drives the expression of the alpha subunit of the elongation factor-1 complex responsible for enzymatic delivery of aminoacyl tRNAs to the ribosome. The EF1a promoter has been widely used in mammalian expression plasmids and has been shown to be effective in driving expression of chimeric receptors from nucleic acids cloned into lentiviral vectors.
[0244] In some embodiments, the promoter capable of expressing the nucleic acid of the present disclosure in mammalian cells (such as immune response cells of the present disclosure) is a constitutive promoter. For example, a suitable constitutive promoter is an immediate early cytomegalovirus (CMV) promoter. The CMV promoter is a strong constitutive promoter capable of driving the high-level expression of any polynucleotide sequence operably connected to the promoter. Other suitable constitutive promoters include but are not limited to ubiquitin C (UbiC) promoter, simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV) promoter, human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukosis virus promoter, Epstein-Barr virus immediate early promoter, Rous sarcoma virus promoter, actin promoter, myosin promoter, elongation factor 1a promoter, hemoglobin promoter and creatine kinase promoter.
[0245] In some embodiments, the promoter capable of expressing the nucleic acid of the present disclosure in mammalian cells (such as the immune response cells of the present disclosure) is an inducible promoter. The use of an inducible promoter can provide a molecular switch capable of inducing or inhibiting the expression of the nucleic acid of the present disclosure when the promoter is operably linked to the nucleic acid. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.
[0246] In some embodiments, the vectors of the present disclosure may further comprise a signal sequence to promote secretion, a polyadenylation signal and a transcription terminator, an element to allow episomal replication, and / or an element to allow selection.
[0247] In some embodiments, the vectors of the present disclosure may further comprise a selective marker gene and / or a reporter gene to facilitate identification and selection of cells expressing the chimeric receptor from a cell population that has been transduced with the vector. In some embodiments, the selective marker may be encoded by a nucleic acid that is separated from the vector and used in a co-transfection procedure. The selective marker or reporter gene may be flanked by appropriate regulatory sequences to allow expression in the host cell. Examples of selective markers include, but are not limited to, antibiotic resistance genes, such as neo and the like.
[0248] In some embodiments, reporter gene can be used to identify transduced cells and for evaluating the functionality of regulatory sequences. As disclosed herein, reporter gene is such a gene, which does not exist in a receptor organism or tissue or is not expressed by a receptor organism or tissue and encodes a polypeptide whose expression causes an easily detectable property (such as enzymatic activity). The expression of reporter gene can be measured at a suitable time after nucleic acid has been introduced into a receptor cell. Examples of reporter genes include but are not limited to genes encoding luciferase, genes encoding beta-galactosidase, genes encoding chloramphenicol acetyltransferase, genes encoding secreted alkaline phosphatase, and genes encoding green fluorescent protein. Suitable expression systems are well known in the art and can be prepared or commercially obtained using known techniques. In some embodiments, the construct with the minimum 5' flanking region showing the highest level of reporter gene expression is identified as a promoter. Such promoter region can be connected to a reporter gene and used to evaluate the ability of a medicament to regulate the transcription driven by a promoter.
[0249] In some embodiments, a vector comprising a nucleic acid sequence encoding an EMCN-specific protein (eg, a chimeric receptor) of the present disclosure further comprises a second nucleic acid encoding a polypeptide that increases the activity of the chimeric receptor.
[0250] In the embodiment that the cell expressing EMCN specific protein comprises two or more heterologous proteins (for example, two or more chimeric receptors), a single nucleic acid can encode two or more proteins under a single regulatory control element (for example, a promoter) or under a separate regulatory control element of a nucleotide sequence of each protein encoding contained in the nucleic acid. In some embodiments where the cell expressing EMCN specific protein comprises two or more heterologous proteins, each heterologous protein can be encoded by a separate nucleic acid. In some embodiments, each separate nucleic acid comprises its own control element (for example, a promoter). In some embodiments, a single nucleic acid encodes two or more chimeric receptors, and the nucleotide sequence encoding the chimeric receptor is in the same reading frame and is expressed as a single polypeptide chain. In such embodiments, the two or more chimeric receptors can be separated by one or more peptide cleavage sites such as an automatic cleavage site or a substrate of an intracellular protease. Suitable peptide cleavage sites may include, but are not limited to, T2A peptide cleavage sites, P2A peptide cleavage sites, E2A peptide cleavage sites, and F2A peptide cleavage sites. In some embodiments, the two or more chimeric receptors include a T2A peptide cleavage site. In some embodiments, the two or more chimeric receptors include an E2A peptide cleavage site. In some embodiments, the two or more chimeric receptors include both T2A and E2A peptide cleavage sites.
[0251] The method of introducing gene into cell and expressing gene is well known in the art.For example, in some embodiments, expression vector can be transferred into host cell by physical means, chemical means or biological means.The example of physical means for introducing nucleic acid into host cell includes but not limited to calcium phosphate precipitation, lipid transfection, particle bombardment, microinjection and electroporation.The example of chemical means for introducing nucleic acid into host cell includes but not limited to colloidal dispersion system, macromolecular complex, nanocapsule, microsphere, pearl and lipid-based system, including oil-in-water emulsion, micelle, mixed micelle and liposome.The example of biological means for introducing nucleic acid into host cell includes but not limited to use DNA and RNA carrier.
[0252] In some embodiments, liposomes can be used as non-viral delivery systems to introduce nucleic acids or vectors of the present disclosure into host cells in vitro, in vitro or in vivo. In some embodiments, the nucleic acid can be associated with lipids, such as by being encapsulated in an aqueous solution inside the liposome, dispersed in the lipid bilayer of the liposome, connected to the liposome via a connecting molecule associated with both the liposome and the nucleic acid, encapsulated in the liposome, compounded with the liposome, dispersed in a solution containing lipids, mixed with lipids, combined with lipids, contained in lipids in the form of a suspension, containing micelles or compounded with micelles, or otherwise associated with lipids. As disclosed herein, lipid-associated nucleic acid or carrier compositions are not limited to any specific structure in solution. In some embodiments, such compositions may be present in a bilayer structure, in the form of micelles, or have a "collapsed" structure. Such compositions may also be dispersed in a solution to form aggregates of uneven size or shape. As disclosed herein, lipids are fatty substances that may be naturally occurring or synthesized. In some embodiments, lipids can include naturally occurring fat droplets in the cytoplasm or contain long-chain aliphatic hydrocarbons and derivatives thereof, such as fatty acids, alcohols, amines, amino alcohols and aldehydes. Suitable lipids can be obtained from commercial sources, and include but are not limited to dimyristylphosphatidylcholine ("DMPC"), dicetyl phosphate ("DCP"), cholesterol and dimyristylphosphatidylglycerol ("DMPG"). The stock solution of lipids in chloroform or chloroform / methanol can be stored at about -20 ° C. Chloroform is used as a solvent because it evaporates more easily than methanol. As used herein, "liposomes" can encompass various monolayers and multilayer lipid vehicles formed by producing encapsulated lipid bilayers or aggregates. In some embodiments, liposomes can be characterized as having a vesicle structure containing a phospholipid bilayer membrane and an internal aqueous medium. In some embodiments, multilayer liposomes can have multiple lipid layers separated by an aqueous medium. Multilayer liposomes can be formed spontaneously when phospholipids are suspended in an excess aqueous solution. In some embodiments, the lipid components may undergo self-rearrangement before forming a closed structure and may trap water and dissolved solutes between the lipid bilayers. In some embodiments, the lipids may present micellar structures or exist only as heterogeneous aggregates of lipid molecules.
[0253] In some embodiments, nucleic acids or vectors of the present disclosure are introduced into mammalian host cells (such as immune response cells of the present disclosure). In some embodiments, the presence of nucleic acids or vectors of the present disclosure in host cells can be confirmed by any suitable assay known in the art, including but not limited to Southern blot assays, Northern blot assays, RT-PCR, PCR, ELISA assays, and Western blot assays.
[0254] In some embodiments, the nucleic acid or vector of the present disclosure is stably transduced into the immune response cell of the present disclosure. In some embodiments, the cell exhibiting stable expression of the nucleic acid or vector expresses the encoded chimeric receptor for at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 3 months, at least 6 months, at least 9 months, or at least 12 months after transduction.
[0255] In embodiments where the EMCN-specific proteins (e.g., chimeric receptors) of the present disclosure are transiently expressed in cells, nucleic acids or vectors encoding EMCN-specific proteins of the present disclosure are transfected into immunoreactive cells of the present disclosure. In some embodiments, immunoreactive cells express EMCN-specific proteins for about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, or about 15 days after transfection.
[0256] In some embodiments, nucleic acid constructs encode bicistronic chimeric antigen receptors. In some embodiments, the encoded bicistronic chimeric antigen receptors include EMCN CARs (such as EMCN inhibitory CARs) and CARs (such as tumor-targeted chimeric receptors) specific to a second antigen.
[0257] In some embodiments, the nucleic acid construct encodes a bivalent chimeric antigen receptor. In some embodiments, the encoded bivalent chimeric antigen receptor comprises an EMCN antigen binding domain and a second antigen binding domain.
[0258] Pharmaceutical compositions and administration
[0259] Certain aspects of the present disclosure relate to compositions (e.g., pharmaceutical compositions) of immunoreactive cells of the present disclosure comprising one or more EMCN-specific proteins of the present disclosure (e.g., chimeric receptors) or expressing such one or more EMCN-specific proteins. In some embodiments, compositions comprising EMCN-specific proteins (e.g., chimeric receptors) or expressing such genetically modified immunoreactive cells of EMCN-specific proteins can be provided systemically or directly to a subject for the treatment of proliferative disorders, such as bone marrow diseases. In certain embodiments, the composition is injected directly into an organ of interest (e.g., an organ affected by an obstacle). Alternatively, the composition can be provided indirectly to an organ of interest, for example, by administration to the circulatory system (e.g., tumor vasculature). Amplifiers and differentiation agents can be provided before, during, or after the administration of the composition to increase the in vitro or in vivo production of T cells, NK cells, or CTL cells.
[0260] Compositions comprising genetically modified cells of the present disclosure may be administered in any physiologically acceptable vehicle, such as intravascularly, although they may also be introduced into the bone or other convenient sites where the genetically modified cells can find appropriate sites for regeneration and differentiation (e.g., the thymus). In some embodiments, at least 1×10 5 cells, eventually reaching 1×10 10 or more cells. The composition including the genetically modified cells of the present disclosure may include a purified cell population. Methods for determining the percentage of genetically modified cells in a cell population are well known in the art, and include but are not limited to fluorescence activated cell sorting (FACS). In some embodiments, the purity of genetically modified cells in a cell population may be about 50%, about 55%, about 60% or about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, about 98%, about 99% or more cells in a cell population. Dosage can be easily adjusted by those skilled in the art (for example, purity reduction may require an increase in dosage). Cells can be introduced by injection, catheter, etc. In some embodiments, factors may also be included, for example, IL-2, IL-3, IL-6, IL-11, IL-7, IL-12, IL-15, IL-21, G-CSF, MCSF, GM-CSF, gamma-interferon and erythropoietin.
[0261] In certain embodiments, the composition is a pharmaceutical composition comprising genetically modified cells (such as immunoreactive cells or their progenitor cells) and a pharmaceutically acceptable carrier. Administration can be autologous or heterologous. For example, immunoreactive cells or progenitor cells can be obtained from a subject and applied to the same subject or different, compatible subjects. In some embodiments, the immunoreactive cells of the present disclosure or their progeny can be derived from peripheral blood cells (e.g., in vivo, ex vivo or in vitro sources) and can be administered by local injection, including catheter administration, systemic injection, local injection, intravenous injection or parenteral administration. When administering the therapeutic composition of the present disclosure (e.g., a pharmaceutical composition containing genetically modified cells of the present disclosure), the therapeutic composition is generally formulated into a unit dose injection form (solution, suspension, emulsion).
[0262] preparation
[0263] Some aspects of the present disclosure relate to the preparation of the composition of the genetically modified cell (for example, immunoreactive cell of the present disclosure) comprising the EMCN specific protein of the present disclosure (for example, chimeric receptor) or expressing such protein.In some embodiments, the composition of the present disclosure comprising genetically modified cells can be provided as a sterile liquid preparation agent, and the preparation agent includes but is not limited to isotonic aqueous solution, suspension, emulsion, dispersion and viscous composition, which can be buffered to selected pH.Liquid preparations are generally easier to prepare than gel, other viscous compositions and solid compositions.In addition, liquid compositions can be more convenient to apply, especially by injection.In some embodiments, viscous compositions can be formulated within an appropriate viscosity range to provide a longer contact period with a specific tissue.Liquid or viscous compositions can include a carrier, and the carrier can be a solvent or dispersion medium containing, for example, water, saline, phosphate buffered saline, polyols (for example, glycerol, propylene glycol, liquid polyethylene glycol, etc.) and a suitable mixture thereof.
[0264] In some embodiments, sterile injection solution can be prepared as needed by mixing the genetically modified cells of the present disclosure dissolved in a sufficient amount of appropriate solvent into any other component of various amounts. Such compositions can be blended with suitable carriers, diluents or excipients (such as sterile water, normal saline, glucose, dextrose, etc.). In some embodiments, the composition can also be lyophilized. Depending on the route of administration and the required preparation, the composition can contain auxiliary substances, such as wetting agents, dispersants, pH buffers and antimicrobial agents.
[0265] In some embodiments, the compositions of the present disclosure may further include various additives that can enhance the stability and sterility of the compositions. Examples of such additives include, but are not limited to, antimicrobial preservatives, antioxidants, chelating agents, and buffers. In some embodiments, microbial contamination may be prevented by including any of various antibacterial and antifungal agents, including, but not limited to, parabens, chlorobutanol, phenol, sorbic acid, and the like. The extended absorption of the injectable pharmaceutical formulations of the present disclosure may be achieved by using suitable delayed absorption agents, such as aluminum monostearate and gelatin.
[0266] In some embodiments, the compositions of the present disclosure can be isotonic, i.e., have the same osmotic pressure as blood and tears. In some embodiments, the desired isotonicity can be achieved using, for example, sodium chloride, dextrose, boric acid, sodium tartrate, propylene glycol, or other inorganic or organic solutes.
[0267] In some embodiments, the components of the formulations of the present disclosure are selected to be chemically inert and not to affect the viability or efficacy of the genetically modified cells of the present disclosure.
[0268] One consideration regarding therapeutic use of the genetically modified cells of the present disclosure is the number of cells required to achieve optimal efficacy. In some embodiments, the number of cells to be administered will vary depending on the subject being treated. In certain embodiments, the number of genetically modified cells administered to a subject in need may be between 1×10 4 cells to 1×10 10 In some embodiments, the exact number of cells considered to be an effective dose can be based on individual factors for each subject, including their build, age, sex, weight, and condition of the particular subject. Based on this disclosure and the knowledge in the art, one skilled in the art can readily determine the dose.
[0269] Heterologous moieties and modifications
[0270] In an additional series of embodiments, the EMCN-specific chimeric proteins herein (eg, EMCN-specific chimeric proteins comprising an antigen binding domain having one or more of the amino acid sequences listed in Table 1) comprise additional moieties and / or modifications.
[0271] Drug conjugates
[0272] In multiple embodiments, a protein comprising an EMCN-specific antigen binding domain as described herein is conjugated to a therapeutic agent (i.e., a drug) to form an antibody-drug conjugate. Therapeutic agents include, but are not limited to, chemotherapeutic agents, imaging agents (e.g., radioisotopes), immunomodulators (e.g., cytokines, chemokines, or checkpoint inhibitors) and toxins (e.g., cytotoxic agents). In certain embodiments, the therapeutic agent is attached to the antigen binding domain via a linker peptide, as discussed in more detail herein.
[0273] Methods for preparing antibody-drug conjugates (ADCs) that can be used to conjugate drugs to the antigen binding domains disclosed herein (e.g., having one or more of the amino acid sequences listed in Table 1) are described, for example, in U.S. Pat. No. 8,624,003 (pot method), U.S. Pat. No. 8,163,888 (one-step method), U.S. Pat. No. 5,208,020 (two-step method), U.S. Pat. No. 8,337,856, U.S. Pat. No. 5,773,001, U.S. Pat. No. 7,829,531, U.S. Pat. No. 5,208,020, U.S. Pat. No. 7,745,394, WO 2017 / 136623, WO 2017 / 015502, WO 2017 / 015496, WO 2017 / 015495, WO 2004 / 010957, WO 2005 / 077090, WO 2005 / 082023, WO 2006 / 065533、WO 2007 / 030642、WO 2007 / 103288、WO2013 / 173337、WO 2015 / 057699、WO 2015 / 095755、WO 2015 / 123679、WO 2015 / 157286、WO2017 / 165851、WO 2009 / 073445、WO 2010 / 068759、WO 2010 / 138719、WO 2012 / 171020、WO2014 / 008375、WO 2014 / 093394、WO 2014 / 093640、WO 2014 / 160360、WO 2015 / 054659, WO2015 / 195925, WO 2017 / 160754, Storz (MAbs. 2015 Nov-Dec; 7(6):989-1009), Lambert et al. (Adv Ther, 2017 34:1015), Diamantis et al. (British Journal of Cancer, 2016, 114, 362-367), Carrico et al. (Nat Chem Biol, 2007.3:321-2), We et al. (Proc Natl Acad Sci USA, 2009.106:3000-5), Rabuka et al. (Current Opin Chem Biol, 2009.107:3000-5), Biol., 201114:790-6), Hudak et al. (Angew Chem Int Ed Engl., 2012:4161-5), Rabuka et al. (Nat Protoc.), 2012 7:1052-67), Agarwal et al. (Proceedings of the National Academy of Sciences of the United States of America, 2013, 110:46-51), Agarwal et al. (Bioconjugate Chem., 2013, 24:846-851, Barfield et al. (Drug Dev. and D., 2014, 14:34-41, Drake et al. (Bioconjugate Chem., 2014, 25:1331-41), Liang et al. (J Am Chem Soc., 2014, 136:10850-3), Drake et al. (Current Opinion in Chemical Biology, 2015, 28:174-80), and York et al. (BMC Biotechnol., 2015, 29:174-80). Biotechnology), 2016, 16(1):23), the entire teachings of each of these documents are hereby incorporated by reference in their entirety.
[0274] Other combined parts
[0275] In various embodiments, the EMCN-specific protein comprises an antigen binding domain having one or more of the amino acid sequences listed in Table 1 and one or more additional binding moieties. In certain embodiments, the binding moiety is an antibody fragment or antibody form, including but not limited to full-length antibodies, Fab fragments, Fv, scFv, tandem scFv, bivalent antibodies, sc bivalent antibodies, DART, tandAb, miniantibodies, camelid VHH, and other antibody fragments or forms known to those skilled in the art. Exemplary antibody and antibody fragment forms are described in detail in Brinkmann et al. (MABS, 2017, Vol. 9, No. 2, 182-212), the entire teachings of which are incorporated herein by reference.
[0276] In a specific embodiment, one or more additional binding moieties are attached to the C-terminus of one or more peptides of an EMCN-specific antigen binding domain, such as a VH and / or VL, a Fab heavy chain and / or light chain fragment, or a scFv. In a specific embodiment, one or more additional binding moieties are attached to the N-terminus of one or more peptides of an EMCN-specific antigen binding domain, such as a VH and / or VL, a Fab heavy chain and / or light chain fragment, or a scFv.
[0277] In certain embodiments, the one or more additional binding moieties are specific for an antigen or epitope different from EMCN. In certain embodiments, the one or more additional binding moieties are specific for EMCN.
[0278] In certain embodiments, one or more additional binding moieties are attached to an antigen binding domain described herein (e.g., having one or more of the amino acid sequences listed in Table 1) using in vitro methods, including but not limited to reaction chemistry (e.g., click chemistry) and affinity tag systems. In certain embodiments, one or more additional binding moieties are attached to an antigen binding domain described herein (e.g., having one or more of the amino acid sequences listed in Table 1) via Fc-mediated binding (e.g., protein A / G). In certain embodiments, one or more additional binding moieties are attached to an antigen binding domain described herein (e.g., having one or more of the amino acid sequences listed in Table 1) using recombinant DNA technology, such as between an antigen binding domain described herein and an additional binding moiety encoding a fusion product on the same expression vector (e.g., plasmid).
[0279] Functional Group / Reactive Group
[0280] In various embodiments, the antigen binding domains described herein (e.g., having one or more of the amino acid sequences listed in Table 1) have modifications comprising functional groups or chemically reactive groups that can be used in downstream processes, such as attachment to additional moieties (e.g., drug conjugates and additional binding moieties) and downstream purification processes.
[0281] In certain embodiments, the modification is a chemically reactive group, including but not limited to reactive thiols (e.g., reactive groups based on maleimide), reactive amines (e.g., reactive groups based on N-hydroxysuccinimide), "click chemistry" groups (e.g., reactive alkyne groups), and aldehydes carrying formylglycine (FGly). In certain embodiments, the modification is a functional group, including but not limited to affinity peptide sequences (e.g., HA, HIS, FLAG, GST, MBP, and Strep systems, etc.). In certain embodiments, the functional group or chemically reactive group has a cleavable peptide sequence. In specific embodiments, the cleavable peptide is cleaved by means including but not limited to: photolysis, chemical cleavage, protease cleavage, reducing conditions, and pH conditions. In specific embodiments, protease cleavage is performed by intracellular proteases. In specific embodiments, protease cleavage is performed by extracellular or membrane-associated proteases. ADC therapy employing protease cleavage is described in more detail in Choi et al. (Theranostics, 2012; 2(2): 156-178.), the entire teachings of which are hereby incorporated by reference.
[0282] Treatment
[0283] Certain aspects of the present disclosure relate to methods for treating a subject in need using EMCN-specific proteins (e.g., chimeric receptors) of the present disclosure and genetically modified cells (e.g., immunoreactive cells) expressing such proteins. In some embodiments, the methods of the present disclosure can be used to treat cancer in a subject, such as a bone marrow disease. In some embodiments, the bone marrow disease is myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia, acute myeloid leukemia (AML), acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, chronic myeloid leukemia, or polycythemia vera. In some embodiments, the bone marrow disease is AML. Other aspects of the present disclosure relate to the use of EMCN-specific chimeric receptors of the present disclosure and genetically modified cells (e.g., immunoreactive cells) expressing such chimeric receptors in methods for treating pathogen infection or other infectious diseases in a subject (such as an immunocompromised human subject). In some embodiments, the method of the present disclosure may include administering the genetically modified cells of the present disclosure in an amount that effectively achieves the desired effect, including but not limited to alleviating existing conditions, preventing conditions, treating existing conditions, managing existing conditions, or preventing the recurrence or repetition of conditions. In some embodiments, an effective amount may be provided in one or a series of administrations of the genetically modified cells of the present disclosure (e.g., immunoreactive cells). In some embodiments, an effective amount may be provided by bolus or by continuous perfusion.
[0284] As disclosed herein, an "effective amount" or "therapeutically effective amount" is an amount sufficient to achieve a beneficial or desired clinical outcome following treatment. An effective amount can be administered to a subject in one or more doses. For treatment, an effective amount is an amount sufficient to alleviate, ameliorate, stabilize, reverse or slow the progression of a disease or otherwise mitigate the pathological consequences of a disease. An effective amount is typically determined on a case-by-case basis by a physician and is within the capabilities of those skilled in the art. Several factors are typically considered in determining an appropriate dosage to achieve an effective amount. These factors include the age, sex, and weight of the subject, the condition being treated, the severity of the condition, and the form and effective concentration of the immunoreactive cells administered.
[0285] For adoptive immunotherapy using antigen-specific cells (e.g., immune-responsive cells such as T cells), approximately 1×10 6 Up to 1×10 10 cells (e.g., about 1×10 9In some embodiments, the induction of immunoreactive cells may include, but is not limited to, inactivating antigen-specific cells such as by loss or anergy. Inactivation is particularly useful for establishing or rebuilding tolerance such as in autoimmune diseases. Genetically modified cells may be administered by any method known in the art, including but not limited to intravenous, subcutaneous, intranodal, intratumoral, intrathecal, intrapleural, intraperitoneal, and direct administration to the thymus.
[0286] In some embodiments, the methods of use encompass methods of suppressing an immune response. Suppressing an immune response may refer to preventing, attenuating or inhibiting a cell-mediated immune response, for example, an immune response induced by a chimeric receptor expressed on the surface of an immunomodulatory cell. In embodiments, the method comprises preventing, attenuating or inhibiting the activation of an activating chimeric receptor expressed on the surface of an immunomodulatory cell.
[0287] In some embodiments, the chimeric inhibitory receptor of the present disclosure is used to prevent, weaken, inhibit or suppress the immune response caused by the tumor-targeted chimeric receptor (e.g., activating CAR).For example, immunomodulatory cells express inhibitory chimeric antigens that recognize antigen target 1 (e.g., non-tumor antigens) and recognize different antigen targets 2 (e.g., tumor targets) of tumor-targeted chimeric receptors.In this example, when immunomodulatory cells contact target cells, inhibitory and tumor-targeted chimeric receptors may or may not be bound to their cognate antigens.In the case of this example, when the target cell is a non-tumor cell expressing both antigen target 1 and antigen target 2, both inhibitory chimeric receptors and tumor-targeted receptors can be activated.In this case, the activation of inhibitory chimeric receptors causes the prevention, weakening or inhibition of tumor-targeted chimeric receptor signaling, and the immunomodulatory cells are not activated.Similarly, in the exemplary example where the target cell is a non-tumor cell that only expresses antigen target 1, only inhibitory chimeric receptors can be activated. In contrast, in the illustrative example where the target cell is a tumor cell that expresses only antigenic target 2, the inhibitory chimeric receptor cannot be activated, while the tumor-targeting chimeric receptor can be activated, thereby causing signal transduction that activates the immunoregulatory cell.
[0288] The inhibition of an immune response triggered by a tumor-targeted chimeric receptor can be an inhibition or reduction of activation of a tumor-targeted chimeric receptor, an inhibition or reduction of signal transduction of a tumor-targeted chimeric receptor, or an inhibition or reduction of activation of an immunomodulatory cell. The inhibitory chimeric receptor can inhibit activation of a tumor-targeted chimeric receptor, signal transduction of a tumor-targeted chimeric receptor, or activation of an immunomodulatory cell by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more times compared to activation of a tumor-targeted chimeric receptor, signal transduction of an immunomodulatory cell, or activation of an immunomodulatory cell lacking the inhibitory chimeric receptor. In some embodiments, inhibition refers to a reduction or decrease in the activity of a tumor-targeted chimeric receptor before or after it is activated.
[0289] The immune response may be the production and secretion of cytokines or chemokines from activated immunoregulatory cells. The immune response may be a cell-mediated immune response against target cells.
[0290] In some embodiments, the chimeric inhibitory receptor is capable of suppressing cytokine production by activated immunoregulatory cells. In some embodiments, the chimeric inhibitory receptor is capable of suppressing a cell-mediated immune response against a target cell, wherein the immune response is induced by activation of an immunoregulatory cell.
[0291] Therapeutic treatment
[0292] In some embodiments, the method of the present disclosure increases the immune response of a subject in need. In some embodiments, the method of the present disclosure includes a method for treating and / or preventing a subject's bone marrow disease. In some embodiments, the subject is a person. In some embodiments, human subjects suitable for therapy may include two treatment groups that can be distinguished by clinical criteria. Subjects with "advanced disease" or "high tumor burden" are subjects carrying clinically measurable tumors. Tumors that can be measured clinically are tumors that can be detected based on tumor mass (e.g., based on the percentage of leukemia cells, measured by palpation, CAT scans, ultrasonography, mammography, or X-ray examinations; self-positive biochemical or histopathological markers are not enough to identify this population). In some embodiments, the pharmaceutical composition of the present disclosure is administered to these subjects to induce an anti-tumor response, with the goal of alleviating the subject's condition. In some embodiments, the reduction of tumor mass occurs due to the administration of the pharmaceutical composition, but any clinical improvement will constitute a benefit. In some embodiments, clinical improvement includes reducing the risk or progression rate of tumors or alleviating their pathological consequences. In some embodiments, the second group of suitable human subjects is an "adjuvant group" subject. These subjects are individuals with a history of bone marrow disease but who have responded to another mode of therapy. Previous therapy may include, but is not limited to, surgical resection, radiotherapy, and / or conventional chemotherapy. Therefore, these individuals do not have clinically measurable tumors. However, they are suspected to be at risk of disease progression near the original tumor site or due to metastasis. In some embodiments, the group can be further subdivided into high-risk individuals and low-risk individuals. Subdivision can be performed based on the features observed before or after initial treatment. These features are known in the clinical field and are appropriately defined for each different bone marrow disease. The typical features of the high-risk subgroups are that the tumor invades adjacent tissues or shows involvement of lymph nodes.
[0293] In any and all aspects of increasing an immune response as described herein, any increase or decrease or change in a characteristic or function is compared to a cell that has not been contacted with an immunoreactive cell as described herein.
[0294] Increasing an immune response can be enhancing an immune response or inducing an immune response. For example, increasing an immune response encompasses starting or initiating an immune response, or enhancing or amplifying an ongoing or existing immune response. In some embodiments, the treatment induces an immune response. In some embodiments, the induced immune response is an adaptive immune response. In some embodiments, the induced immune response is an innate immune response. In some embodiments, the treatment enhances an immune response. In some embodiments, the enhanced immune response is an adaptive immune response. In some embodiments, the enhanced immune response is an innate immune response. In some embodiments, the treatment increases an immune response. In some embodiments, the increased immune response is an adaptive immune response. In some embodiments, the increased immune response is an innate immune response.
[0295] In some embodiments, another group of subjects are those with a genetic predisposition to bone marrow disease but the clinical signs of bone marrow disease have not yet been confirmed. For example, for women who are positive for the genetic mutation test related to AML but are still in childbearing age, it is possible to benefit from receiving one or more of the disclosed cells (e.g., immunoreactive cells) in preventive treatment to prevent the occurrence of AML until it is suitable for preventive surgery. In some embodiments, the subject may suffer from advanced disease forms, in which case the treatment goal may include mitigation or reversal of disease progression and / or improvement of side effects. In some embodiments, the subject may have a history of illness, and they have been treated, in which case the treatment goal may generally include a reduction or delay in the risk of recurrence.
[0296] Combination therapy
[0297] In some embodiments, genetically modified cells (e.g., immunoreactive cells) of the present disclosure expressing one or more proteins (comprising antigen binding domains (e.g., scFv) of the present disclosure, such as chimeric receptors of the present disclosure) can be used in combination with other known agents and therapies. In some embodiments, the combination therapy of the present disclosure includes genetically modified cells of the present disclosure, which can be administered in combination with one or more additional therapeutic agents. In some embodiments, the genetically modified cells and one or more additional therapeutic agents can be administered simultaneously, in the same or separate compositions, or sequentially. For sequential administration, the genetic modification can be administered first, and then one or more additional agents can be administered, or the order of administration can be reversed. In some embodiments, the genetically modified cells are further modified to express one or more additional therapeutic agents.
[0298] In some embodiments, the genetically modified cells of the present disclosure can be used in a treatment regimen in combination with surgery, chemotherapy, radiotherapy, immunosuppressants (e.g., cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, and FK506), antibodies or other immunoablative agents (e.g., CAMPATH or anti-CD3 antibodies), cytotoxins, fludarabme, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, irradiation, and peptide vaccines.
[0299] In some embodiments, the genetically modified cells of the present disclosure can be used in combination with a lymphocyte depleting agent. Prior to immunotherapy, a suitable lymphocyte depleting agent reduces or decreases lymphocytes, e.g., B cell lymphocytes and / or T cell lymphocytes. Examples of suitable lymphocyte depleting agents include, but are not limited to, fludarabine, cyclophosphamide, corticosteroids, alemtuzumab, total body irradiation (TBI), and any combination thereof.
[0300] In some embodiments, the genetically modified cells of the present disclosure can be used in combination with chemotherapeutic agents. Suitable chemotherapeutic agents include, but are not limited to, anthracyclines (e.g., doxorubicin), vinca alkaloids (e.g., vinblastine, vincristine, vindesine, vinorelbine), alkylating agents (e.g., cyclophosphamide, decarbazine, melphalan, ifosfamide, temozolomide, mide), immune cell antibodies (e.g., alemtuzamab, gemtuzumab, rituximab, tositumomab), antimetabolites (e.g., folate antagonists, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors such as fludarabine), mTOR inhibitors, TNFR glucocorticoid-induced TNFR-related protein (GITR) agonists, proteasome inhibitors (e.g., aclacinomycin A, gliotoxin, or bortezomib), immunomodulators (such as thalidomide or a thalidomide derivative) (e.g., lenalidomide).
[0301] Examples of general chemotherapeutic agents suitable for combination therapy include, but are not limited to, anastrozole Bicalutamide Bleomycin sulfate busulfan Busulfan Injection Capecitabine N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin Carmustine Chlorambucil Cisplatin Cladribine Cyclophosphamide or ), cytarabine, cytosine arabinoside Cytarabine liposome injection Dacarbazine Actinomycin D (cosmegan), daunorubicin hydrochloride Daunorubicin citrate liposome injection Dexamethasone, docetaxel Doxorubicin hydrochloride Etoposide Fludarabine phosphate 5-Fluorouracil Flutamide Tezacitibine, Gemcitabine (difluorodeoxycytidine), Hydroxyurea Idarubicin Ifosfamide Irinotecan L-Asparaginase Calcium leucovorin, melphalan 6-Mercaptopurine Methotrexate Mitoxantrone mylotarg, paclitaxel Phoenix (yttrium 90 / MX-DTPA), pentostatin, polifeprosan 20 and carmustine implants Tamoxifen citrate Teniposide 6-thioguanine, thiotepa, tirapazamine Topotecan hydrochloride for injection Vinblastine Vincristine Vinorelbine
[0302] Examples of suitable alkylating agents include, but are not limited to, nitrogen mustards, ethyleneimine derivatives, alkyl sulfonates, nitrosoureas and triazenes, uracil mustard, Uracil nitrogen ), chlormethine Cyclophosphamide ( Rev immune TM ), ifosfamide Melphalan Chlorambucil Pipobroman Triethylenemelamine Triethylenethiophosphoramide, Temozolomide Thiotepa Busulfan Carmustine Lomustine Streptozocin and dacarbazine Additional exemplary alkylating agents include, but are not limited to, oxaliplatin Temozolomide ( and ); Actinomycin D (also known as actinomycin-D, ); Melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, ); Altretamme (also known as hexamethylmelamine (HMM), ); Carmustine Bendamustine Busulfan and ); Carboplatin Lomustine (also known as CCNU, ); cisplatin (also known as CDDP, and -AQ); Chlorambucil Cyclophosphamide ( and ); Dacarbazine (also known as DTIC, DIC, and imidazole carboxamide, ); Atetraamine (also known as hexamethylmelamine (HMM), ); ifosfamide Prednumustine; Procarbazine Mechlorethamine (also known as nitrogen mustard, mustard, and mechlorethamine hydrochloride, ); Streptozotocin Thiotepa (also known as thiophosphoramide, TESPA, and TSPA, ); Cyclophosphamide and bendamustine HC1
[0303] Examples of suitable mTOR inhibitors include, but are not limited to, temsirolimus, ridaforolimus (deferolimus), AP23573, MK8669, everolimus ( or RADOOl), rapamycin (AY22989, ) and XL765.
[0304] Examples of suitable immunomodulators include, but are not limited to, afutuzumab, pegfilgrastim Lenalidomide (CC-5013, ), Thalidomide Actimid (CC4047) and IRX-2.
[0305] Examples of suitable anthracyclines include, but are not limited to, doxorubicin ( and );bleomycin Daunorubicin (daunorubicin hydrochloride, daunomyem, and rubidomycin hydrochloride), ); daunorubicin liposomes (daunorubicin citrate liposomes, ); Mitoxantrone (DHAD, ); epirubicin (Ellence TM ); Idabi ( Idamycin ); Mitomycin C geldanamycin; herbimycin; ravidomycin; and desacetyl aravidomycin.
[0306] Examples of suitable vinca alkaloids include, but are not limited to, vinorelbine tartrate Vincristine Vindesine Vinblastine (also known as vinblastine sulfate, vincaleukoblastine, and VLB, and ); and vinorelbine
[0307] Examples of suitable proteasome inhibitors include, but are not limited to, bortezomib carfilzomib; marizomib (NPI-0052); ixazomib citrate (MLN-9708); delanzomib (CEP-18770); and ONX-0912.
[0308] In some embodiments, the genetically modified cells of the present disclosure are administered in combination with a CD20 inhibitor (e.g., an anti-CD20 antibody) or a fragment thereof. Exemplary anti-CD20 antibodies include, but are not limited to, rituximab, ofatumumab, ocrelizumab, veltuzumab, obinutuzumab, TRU-015 (Trubion Pharmaceuticals), ocaratuzumab, and Prol31921.
[0309] In some embodiments, the genetically modified cells of the present disclosure are administered in combination with oncolytic viruses. In some embodiments, oncolytic viruses can selectively replicate in cancer cells and trigger the death of cancer cells or slow the growth of cancer cells. In some cases, oncolytic viruses have no effect or little effect on non-cancerous cells. Suitable oncolytic viruses include but are not limited to oncolytic adenoviruses, oncolytic herpes simplex viruses, oncolytic retroviruses, oncolytic parvoviruses, oncolytic vaccinia viruses, oncolytic Sindbis viruses (oncolytic Sindbis virus), oncolytic influenza viruses, or oncolytic RNA viruses (e.g., oncolytic reoviruses, oncolytic Newcastle Disease Virus (Newcastle Disease Virus; NDV), oncolytic measles viruses, or oncolytic vesicular stomatitis viruses (VSV)). In some embodiments, oncolytic viruses are recombinant oncolytic viruses.
[0310] In some embodiments, the genetically modified cells of the present disclosure are administered to a subject in combination with a protein tyrosine phosphatase inhibitor (e.g., a SHP-I inhibitor or a SHP-2 inhibitor). In one embodiment, the genetically modified cells of the present disclosure can be used in combination with a kinase inhibitor. Examples of suitable kinase inhibitors include, but are not limited to, CDK4 inhibitors, CDK4 / 6 inhibitors, BTK inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, mTOR inhibitors, MNK inhibitors, and anaplastic lymphoma kinase (ALK) inhibitors.
[0311] In some embodiments, the genetically modified cells of the present disclosure are administered to a subject in combination with a regulator of myeloid-derived suppressor cells (MDSC). MDSC accumulates in the periphery and tumor site of many solid tumors. These cells suppress T cell responses, thereby hindering the efficacy of cell therapies expressing chimeric receptors. Without being bound by theory, it is believed that the administration of MDSC regulators enhances the efficacy of the genetically modified cells of the present disclosure. Examples of suitable MDSC regulators include, but are not limited to, MCS110 and BLZ945.
[0312] In some embodiments, the genetically modified cells of the present disclosure are administered to a subject in combination with an agent that inhibits or reduces the activity of immunosuppressive plasma cells. Immunosuppressive plasma cells have been shown to hinder T cell-dependent immunogenic chemotherapy, such as oxaliplatin (Shalapour et al., Nature 2015, 521: 94-101). In one embodiment, immunosuppressive plasma cells may express one or more of IgA, interleukin (IL)-10, and PD-L1.
[0313] In some embodiments, the genetically modified cells of the present disclosure are administered to a subject together with an interleukin-15 (IL-15) polypeptide, an interleukin-15 receptor alpha (IL-15Ra) polypeptide, or a combination of an IL-15 polypeptide and an IL-15Ra polypeptide. In some embodiments, the genetically modified cells of the present disclosure are further modified to express an interleukin-15 (IL-15) polypeptide, an interleukin-15 receptor alpha (IL-15Ra) polypeptide, or a combination of an IL-15 polypeptide and an IL-15Ra polypeptide.
[0314] In some embodiments, a subject with a bone marrow disease (e.g., AML) is administered a combination of a genetically modified cell of the present disclosure and a pharmaceutical agent (e.g., a cytotoxic agent or a chemotherapeutic agent), a biological therapy (e.g., an antibody, e.g., a monoclonal antibody, or a cell therapy) or an inhibitor (e.g., a kinase inhibitor). In some embodiments, a subject is administered a combination of a genetically modified cell of the present disclosure and a cytotoxic agent, such as CPX-351 (Celator Pharmaceuticals), cytarabine, daunorubicin, vosaroxin (Sunesis Pharmaceuticals), sapacitabine (sapacitabine) (Cyclacel Pharmaceuticals), idarubicin or mitoxantrone. CPX-351 is a liposomal formulation comprising cytarabine and daunorubicin in a molar ratio of 5: 1. In some embodiments, a subject is administered a combination of a cell expressing a chimeric receptor as described herein and a hypomethylating agent, such as a DNA methyltransferase inhibitor, such as azacytidine or decitabine. In some embodiments, a subject is administered a genetically modified cell of the present disclosure in combination with a biotherapeutic, such as an antibody or a cell therapeutic, e.g., 225Ac-lintuzumab (Actimab-A; Actinium Pharmaceuticals), IPH2102 (Innate Pharma / Bristol Myers Squibb), SGN-CD33A (Seattle Genetics), or gemtuzumab ozogamicin (Mylotarg; Pfizer). In some embodiments, the subject is administered a combination of a genetically modified cell of the present invention and a FLT3 inhibitor, such as sorafenib (Bayer), midostaurin (Novartis), quizartinib (Daiichi Sankyo), crenoianib (Arog Pharmaceuticals), PLX3397 (Daiichi Sankyo), AKN-028 (Akinion Pharmaceuticals) or ASP2215 (Astelias). In some embodiments, the subject is administered a combination of a genetically modified cell of the present invention and an isocitrate dehydrogenase (IDH) inhibitor, such as AG-221 (Celgene / Agios) or AG-120 (Agios / Celgene).In some embodiments, the subject is administered a combination of genetically modified cells of the present disclosure and a cell cycle regulator, such as an inhibitor of Polo-like kinase 1 (Plkl), such as volasertib (Boehringer Ingelheim); or an inhibitor of cyclin-dependent kinase 9 (Cdk9), such as avocidib (Tolero Pharmaceuticals / Sanofi Aventis). In some embodiments, the subject is administered a combination of genetically modified cells of the present disclosure and a B cell receptor signaling network inhibitor, such as a B cell lymphoma 2 (Bcl-2) inhibitor, such as venetoclax (Abbvie / Roche); or an inhibitor of Button tyrosine kinase (Btk), such as ibrutinib (Pharmacyclics / Johnson & Johnson Janssen Pharmaceutical). In some embodiments, the genetically modified cells of the present disclosure are administered to a subject in combination with an inhibitor of M1 aminopeptidase; an inhibitor of histone deacetylase (HDAC), such as pracinostat (MEIPharma); a multikinase inhibitor, such as rigosertib (Onconova Therapeutics / Baxter / SymBio); or a peptide CXCR4 inverse agonist, such as BL-8040 (BioLineRx).
[0315] In some embodiments, the subject may be administered an agent that enhances the activity or fitness of the genetically modified cells disclosed herein. For example, an agent may inhibit a molecule that regulates or modulates (e.g., inhibits) T cell function. In some embodiments, the molecule that regulates or modulates T cell function is an inhibitory molecule. In some embodiments, an inhibitory molecule (such as programmed death 1 (PD-1)) may reduce the ability of genetically modified cells to produce immune effector responses. Examples of suitable inhibitory molecules include, but are not limited to, PD-1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and / or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LIR-1 (LILRB1), CD 160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFβ. Inhibition of molecules that regulate or modulate (e.g., inhibit) T cell function, such as by inhibiting at the DNA, RNA, or protein level, can optimize the performance of the genetically modified cells of the present disclosure. In some embodiments, agents, such as inhibitory nucleic acids, such as inhibitory nucleic acids, such as inhibitory nucleic acids, such as dsRNA, such as siRNA or shRNA, clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nucleases (TALEN) or zinc finger endonucleases (ZFN), can be used to inhibit the expression of inhibitory molecules in genetically modified cells. In one embodiment, the inhibitor is shRNA. In some embodiments, the genetically modified cells of the present disclosure can be further modified to express inhibitory nucleic acids, such as inhibitory nucleic acids, such as inhibitory nucleic acids, such as dsRNA, such as siRNA or shRNA, clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nucleases (TALEN) or zinc finger endonucleases (ZFN), which can be used to inhibit the expression of inhibitory molecules in genetically modified cells.
[0316] In one embodiment, the agent regulating or regulating (e.g., inhibiting) T cell function is suppressed in the genetically modified cells of the present disclosure. In such embodiments, the dsRNA molecules that suppress the expression of molecules regulating or regulating (e.g., inhibiting) T cell function are connected to the nucleic acid encoding the components (e.g., all components) of the chimeric receptor of the present disclosure. In one embodiment, the nucleic acid molecules encoding the dsRNA molecules that suppress the expression of molecules regulating or regulating (e.g., inhibiting) T cell function are operably connected to promoters, such as promoters derived from HI or U6, so that the dsRNA molecules that suppress the expression of molecules regulating or regulating (e.g., inhibiting) T cell function are expressed, such as expressed in genetically modified cells. In one embodiment, the nucleic acid molecules encoding the dsRNA molecules that suppress the expression of molecules regulating or regulating (e.g., inhibiting) T cell function are present in the same vector (e.g., lentiviral vector) of the nucleic acid molecules that comprise the components (e.g., all components) of the encoding chimeric receptor. In this embodiment, the nucleic acid molecule encoding the dsRNA molecule that inhibits the expression of the molecule that regulates or modulates (e.g., inhibits) T cell function is located at the 5'- or 3'-end of the nucleic acid encoding the components (e.g., all components) of the chimeric receptor on the vector (e.g., lentiviral vector). The nucleic acid molecule encoding the dsRNA molecule that inhibits the expression of the molecule that regulates or modulates (e.g., inhibits) T cell function can be transcribed in the same or different direction as the nucleic acid encoding the components (e.g., all components) of the chimeric receptor. In one embodiment, the nucleic acid molecule encoding the dsRNA molecule that inhibits the expression of the molecule that regulates or modulates (e.g., inhibits) T cell function is present on a vector other than the vector containing the nucleic acid molecule encoding the components (e.g., all components) of the chimeric receptor. In one embodiment, the nucleic acid molecule encoding the dsRNA molecule that inhibits the expression of the molecule that regulates or modulates (e.g., inhibits) T cell function is transiently expressed in the genetically modified cell. In one embodiment, the nucleic acid molecule encoding the dsRNA molecule that inhibits the expression of the molecule that regulates or modulates (e.g., inhibits) T cell function is stably integrated into the genome of the genetically modified cell of the present disclosure.
[0317] In one embodiment, the agent that regulates or controls (e.g., inhibits) T cell function can be an antibody or antibody fragment that binds to an inhibitory molecule. For example, the agent can be an antibody or antibody fragment that binds to PD-1, PD-L1, PD-L2, or CTLA4. In one embodiment, the agent is an antibody or antibody fragment that binds to TIM3. In one embodiment, the agent is an antibody or antibody fragment that binds to LAG3.
[0318] In some embodiments, the agent that enhances the activity of the genetically modified cells is a CEACAM inhibitor (e.g., CEACAM-1, CEACAM-3 and / or CEACAM-5 inhibitor). In one embodiment, the inhibitor of CEACAM is an anti-CEACAM antibody molecule. In one embodiment, the agent that enhances the activity of the genetically modified cells of the present disclosure is miR-17-92. In some embodiments, the agent that enhances the activity of the genetically modified cells is CD40L. In some embodiments, the agent that enhances the activity of the genetically modified cells is GM-CSF. In some embodiments, the genetically modified cells of the present disclosure are further modified to express antibodies or antibody fragments that bind to inhibitory molecules of the present disclosure.
[0319] In one embodiment, the medicament that enhances the activity of the genetically modified cells of the present disclosure is a cytokine.Cytokines have important functions related to immunoreactive cell expansion, differentiation, survival and homeostasis.Cytokines that can be applied to the subject of the genetically modified cells of the present disclosure include but are not limited to IL-2, IL-4, IL-7, IL-9, IL-12, L-15, IL-18 and IL-21 or a combination thereof.Cytokines can be applied once a day or multiple times a day, for example, twice a day, three times a day or four times a day.Cytokines can be applied for more than one day, for example, cytokines are applied for 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks or 4 weeks.For example, cytokines are applied once a day for 7 days.In some embodiments, the genetically modified cells of the present disclosure are further modified to express one or more cytokines, such as IL-2, IL-4, IL-7, IL-9, IL-12, L-15, IL-18 and IL-21.
[0320] In some embodiments, cytokines can be used simultaneously or synchronously with genetically modified cells, for example, on the same day.Cytokines can be prepared in the pharmaceutical composition identical with genetically modified cells, or can be prepared in a separate pharmaceutical composition.Or, cytokines can be used soon after using genetically modified cells, for example, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days or 7 days after using genetically modified cells.In some embodiments of using cytokines in the application scheme of more than one day, the first day of the cytokine application scheme can be the same day as the application of genetically modified cells, or the first day of the cytokine application scheme can be 1 day, 2 days, 3 days, 4 days, 5 days, 6 days or 7 days after using genetically modified cells.In one embodiment, on the first day, genetically modified cells are applied to subjects, and on the second day, cytokines are applied once every day in the next 7 days. In some embodiments, the cytokine is administered for a period of time after the administration of the genetically modified cells, such as at least 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 1 year or longer after the administration of the genetically modified cells. In one embodiment, the cytokine is administered after assessing the subject's response to the genetically modified cells.
[0321] Reagent test kit
[0322] Some aspects of the present disclosure relate to a kit for treating and / or preventing cancer (e.g., AML) or other diseases (e.g., immune-related or autoimmune diseases). In certain embodiments, the kit comprises a therapeutic or preventive composition, the composition comprising an effective amount of one or more proteins, the protein comprising an antigen binding domain (e.g., scFv) of the present disclosure (such as a chimeric receptor of the present disclosure), a nucleic acid of the separation of the present disclosure, a carrier of the present disclosure and / or a cell of the present disclosure (e.g., an immunoreactive cell). In some embodiments, the kit includes a sterile container. In some embodiments, such containers can be boxes, ampoules, bottles, vials, tubes, bags, pouches, blister packs or other suitable container forms as known in the art. The container can be made of plastic, glass, laminated paper, metal foil or other materials suitable for accommodating medicine.
[0323] In some embodiments, therapeutic or preventive compositions are provided together with instructions for applying the therapeutic or preventive compositions to subjects suffering from cancer (e.g., AML) or a risk of developing cancer. In some embodiments, instructions may include information about using the compositions to treat and / or prevent disorders. In some embodiments, instructions include but are not limited to descriptions of the therapeutic or preventive compositions, dosage schedules, schedules for administration for treating or preventing illnesses or their symptoms, precautions, warnings, indications, counterindications, overdose information, adverse reactions, animal pharmacology, clinical studies, and / or references. In some embodiments, instructions may be printed directly on the container (when present), or as a label applied to the container, or as a separate paper, brochure, card, or folder provided in or with the container.
[0324] List of implementation plans
[0325] Embodiment 1: An isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) region and a light chain variable (VL) region,
[0326] a. wherein the VH comprises a VH complementary region 1 (CDRH1) having an amino acid sequence of SEQ ID NO: 1, a VH complementary region 2 (CDRH2) having an amino acid sequence of SEQ ID NO: 6, and a VH complementary region 3 (CDRH3) having an amino acid sequence of SEQ ID NO: 8;
[0327] b. wherein the VL comprises a VL complementary region 1 (CDRL1) having an amino acid sequence of SEQ ID NO: 9, a VL complementary region 2 (CDRL2) having an amino acid sequence of SEQ ID NO: 10, and a VL complementary region 3 (CDRL3) having an amino acid sequence of SEQ ID NO: 11; and
[0328] c. wherein the antibody or antigen-binding fragment thereof is humanized.
[0329] Embodiment 2: An isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) region and a light chain variable (VL) region,
[0330] a. wherein the VH comprises a VH complementary region 1 (CDRH1) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-5, a VH complementary region 2 (CDRH2) having an amino acid sequence of SEQ ID NO: 7, and a VH complementary region 3 (CDRH3) having an amino acid sequence of SEQ ID NO: 8;
[0331] b. wherein the VL comprises a VL complementary region 1 (CDRL1) having an amino acid sequence of SEQ ID NO: 9, a VL complementary region 2 (CDRL2) having an amino acid sequence of SEQ ID NO: 10, and a VL complementary region 3 (CDRL3) having an amino acid sequence of SEQ ID NO: 11, and
[0332] c. wherein the antibody or antigen-binding fragment thereof is humanized.
[0333] Embodiment 3: An isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) region and a light chain variable (VL) region,
[0334] a. wherein the VH comprises a VH complementary region 1 (CDRH1) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-5, a VH complementary region 2 (CDRH2) having an amino acid sequence of SEQ ID NO: 7, and a VH complementary region 3 (CDRH3) having an amino acid sequence of SEQ ID NO: 8; and
[0335] b. wherein the VL comprises a VL complementary region 1 (CDRL1) having the amino acid sequence of SEQ ID NO:9, a VL complementary region 2 (CDRL2) having the amino acid sequence of SEQ ID NO:10, and a VL complementary region 3 (CDRL3) having the amino acid sequence of SEQ ID NO:11.
[0336] Embodiment 4: The antibody or antigen-binding fragment thereof as described in Embodiment 2 or Embodiment 3, wherein the CDRH1 has the amino acid sequence as shown in SEQ ID NO:2.
[0337] Embodiment 5: The antibody or antigen-binding fragment thereof of any one of embodiments 1 to 4, wherein the VH has an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15.
[0338] Embodiment 6: The antibody or antigen-binding fragment thereof as described in Embodiment 5, wherein the VH has the amino acid sequence as shown in SEQ ID NO:12.
[0339] Embodiment 7: The antibody or antigen-binding fragment thereof as described in any one of Embodiments 1 to 6, wherein the VH has an amino acid sequence selected from the group consisting of: SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19.
[0340] Embodiment 8: The antibody or antigen-binding fragment thereof as described in Embodiment 7, wherein the VH has the amino acid sequence as shown in SEQ ID NO:16.
[0341] Embodiment 9: The antibody or antigen-binding fragment thereof as described in any one of Embodiments 1 to 8, wherein the VL has an amino acid sequence as shown in SEQ ID NO:20.
[0342] Embodiment 10: An isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH comprises a heavy chain complementary determining region 1 (CDR-H1), a heavy chain complementary determining region 2 (CDR-H2), and a heavy chain complementary determining region 3 (CDR-H3), the CDR-H1, the CDR-H2, and the CDR-H3 are contained within a VH having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12-19, and wherein the VL comprises a light chain complementary determining region 1 (CDR-L1), a light chain complementary determining region 2 (CDR-L2), and a light chain complementary determining region 3 (CDR-L3), the CDR-L1, the CDR-L2, and the CDR-L3 are contained within a VL having an amino acid sequence of SEQ ID NO: 20.
[0343] Embodiment 11: An isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising a variable heavy chain (VH) region and a variable light chain (VL) region, wherein the VL has an amino acid sequence as shown in SEQ ID NO:20.
[0344] Embodiment 12: An isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising a variable heavy chain (VH) region and a variable light chain (VL) region, wherein the VH has an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19.
[0345] Embodiment 13: The antibody or antigen-binding fragment thereof as described in any one of Embodiments 10 to 12, wherein the VH has an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:15.
[0346] Embodiment 14: The antibody or antigen-binding fragment thereof as described in Embodiment 13, wherein the VH has the amino acid sequence as shown in SEQ ID NO:12.
[0347] Embodiment 15: The antibody or antigen-binding fragment thereof as described in any one of Embodiments 10 to 12, wherein the VH has an amino acid sequence selected from the group consisting of: SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:19.
[0348] Embodiment 16: The antibody or antigen-binding fragment thereof as described in Embodiment 15, wherein the VH has the amino acid sequence as shown in SEQ ID NO:16.
[0349] Embodiment 17: An antibody or antigen-binding fragment thereof as described in any one of Embodiment 10 and Embodiments 12 to 16, wherein the VL has an amino acid sequence as shown in SEQ ID NO: 20.
[0350] Embodiment 18: The antibody or antigen-binding fragment thereof as described in any one of Embodiments 1 to 17, wherein the antibody or antigen-binding fragment thereof is an antigen-binding fragment.
[0351] Embodiment 19: The antibody or antigen-binding fragment thereof as described in Embodiment 18, wherein the antigen-binding fragment comprises a F(ab) fragment, a F(ab') fragment or a single-chain variable fragment (scFV).
[0352] Embodiment 20: The antibody or antigen-binding fragment thereof as described in Embodiment 19, wherein the antigen-binding fragment comprises a single-chain variable fragment (scFv).
[0353] Embodiment 21: The antibody or antigen-binding fragment thereof as described in Embodiment 20, wherein the VH and the VL of the scFv are separated by a peptide linker.
[0354] Embodiment 22: An antibody or antigen-binding fragment thereof as described in Embodiment 21, wherein the antigen-binding domain comprises the structure VH-L-VL or VL-L-VH, wherein VH is a heavy chain variable domain, L is a peptide linker, and VL is a light chain variable domain.
[0355] Embodiment 23: An antibody or antigen-binding fragment thereof as described in Embodiment 21 or Embodiment 22, wherein the peptide linker comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 21-37.
[0356] Embodiment 24: An antibody or antigen-binding fragment thereof as described in any one of Embodiments 20 to 23, wherein the scFv comprises an amino acid sequence selected from the group consisting of: SEQ ID No: 65, 67, 69 and 70.
[0357] Embodiment 25: A chimeric protein comprising the antibody or antigen-binding fragment thereof as described in any one of Embodiments 1 to 24, and a heterologous molecule or portion.
[0358] Embodiment 26: A chimeric protein as described in embodiment 25, wherein the chimeric protein is an antibody-drug conjugate and wherein the heterologous molecule or portion comprises a therapeutic agent.
[0359] Embodiment 27: A chimeric protein as described in embodiment 25, wherein the chimeric protein is a chimeric antigen receptor (CAR), and wherein the heterologous molecule or portion comprises a polypeptide selected from the group consisting of: a transmembrane domain, one or more intracellular signaling domains, a hinge domain, a spacer, one or more peptide linkers, and combinations thereof.
[0360] Embodiment 28: A chimeric protein as described in embodiment 27, wherein the CAR comprises a transmembrane domain.
[0361] Embodiment 29: A chimeric protein as described in embodiment 27 or embodiment 28, wherein the CAR comprises one or more intracellular signaling domains.
[0362] Embodiment 30: A chimeric protein as described in any one of embodiments 27 to 29, wherein the CAR is an activating CAR comprising one or more intracellular signaling domains that stimulate an immune response.
[0363] Embodiment 31: A chimeric protein as described in any one of embodiments 27 to 29, wherein the CAR is an inhibitory CAR comprising one or more intracellular inhibitory domains that inhibit an immune response.
[0364] Embodiment 32: A chimeric protein as described in embodiment 31, wherein the intracellular inhibitory domain comprises an enzyme inhibitory domain.
[0365] Embodiment 33: A chimeric protein as described in embodiment 31 or embodiment 32, wherein the intracellular inhibitory domain includes an intracellular inhibitory co-signaling domain.
[0366] Embodiment 34: A chimeric protein as described in any one of embodiments 27 to 33, wherein the CAR comprises a spacer region between the antigen binding domain and the transmembrane domain.
[0367] Embodiment 35: A chimeric protein as described in embodiment 34, wherein the spacer region has an amino acid sequence selected from the group consisting of SEQ ID NO:41-52.
[0368] Embodiment 36: A composition comprising the antibody or antigen-binding fragment thereof as described in any one of Embodiments 1 to 24, or the chimeric protein as described in any one of Embodiments 25 to 35, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof.
[0369] Embodiment 37: An engineered nucleic acid encoding an antibody or antigen-binding fragment as described in any one of embodiments 1 to 24 or a chimeric protein as described in any one of embodiments 25 to 35.
[0370] Embodiment 38: An expression vector comprising the engineered nucleic acid described in Embodiment 37.
[0371] Embodiment 39: A composition comprising the engineered nucleic acid as described in Embodiment 37 or the expression vector as described in Embodiment 38 and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof.
[0372] Embodiment 40: A method for preparing engineered cells, the method comprising transducing isolated cells with the engineered nucleic acid as described in Embodiment 37 or the expression vector as described in Embodiment 38.
[0373] Embodiment 41: An isolated cell comprising the engineered nucleic acid as described in embodiment 37, the expression vector as described in embodiment 38, or the composition as described in embodiment 39.
[0374] Embodiment 42: An engineered cell population, which expresses the engineered nucleic acid described in Embodiment 37 or the expression vector described in Embodiment 38.
[0375] Embodiment 43: An isolated cell comprising an antigen binding fragment as described in any one of embodiments 1 to 24 or a chimeric protein as described in any one of embodiments 25 to 35.
[0376] Embodiment 44: An engineered cell population expressing an antigen binding fragment as described in any one of embodiments 1 to 24 or a chimeric protein as described in any one of embodiments 25 to 35.
[0377] Embodiment 45: A cell or cell population as described in any one of embodiments 41 to 44, wherein the chimeric protein is recombinantly expressed.
[0378] Embodiment 46: A cell or cell population as described in any one of embodiments 41 to 45, wherein the chimeric protein is expressed from a vector or from a selected locus in the genome of the cell.
[0379] Embodiment 47: The cell or cell population of any one of claims 41 to 46, wherein the cell or cell population further comprises one or more tumor-targeting chimeric receptors expressed on the cell surface.
[0380] Embodiment 48: A cell or cell population as described in embodiment 47, wherein each of the one or more tumor-targeting chimeric receptors is a chimeric antigen receptor (CAR) or an engineered T cell receptor.
[0381] Embodiment 49: A cell or cell population as described in any one of embodiments 41 to 48, wherein the cell or cell population is selected from the group consisting of: T cells, CD8+T cells, CD4+T cells, γ-δT cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, virus-specific T cells, natural killer T (NKT) cells, natural killer (NK) cells, B cells, tumor infiltrating lymphocytes (TILs), innate lymphoid cells, mast cells, eosinophils, basophils, neutrophils, bone marrow cells, macrophages, monocytes, dendritic cells, erythrocytes, platelet cells, human embryonic stem cells (ESCs), ESC-derived cells, pluripotent stem cells, mesenchymal stromal cells (MSCs), induced pluripotent stem cells (iPSCs), and iPSC-derived cells.
[0382] Embodiment 50: A cell or cell population as described in any one of embodiments 41 to 49, wherein the cells are autologous.
[0383] Embodiment 51: A cell or cell population as described in any one of embodiments 41 to 49, wherein the cells are allogeneic.
[0384] Embodiment 52: A pharmaceutical composition comprising an effective amount of a cell or engineered cell population as described in any one of Embodiments 41 to 51 and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof.
[0385] Embodiment 53: A pharmaceutical composition comprising an effective amount of genetically modified cells expressing the antigen binding fragment of any one of Embodiments 1 to 24 or the chimeric protein of any one of Embodiments 25 to 35 and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof.
[0386] Embodiment 54: A pharmaceutical composition as described in Embodiment 52 or Embodiment 53, for treating and / or preventing tumors.
[0387] Embodiment 55: A method of treating a subject in need thereof, the method comprising administering a therapeutically effective dose of a composition as described in embodiment 36 or embodiment 39, or any of the cells as described in any one of embodiments 41 to 51, or a pharmaceutical composition as described in embodiment 52 or embodiment 53.
[0388] Embodiment 56: A method for stimulating a cell-mediated immune response against tumor cells in a subject, the method comprising administering to a subject having a tumor a therapeutically effective dose of a composition as described in embodiment 36 or embodiment 39, or any of the cells as described in any one of embodiments 41 to 51, or a composition as described in embodiment 52 or embodiment 53.
[0389] Embodiment 57: A method as described in embodiment 56, comprising administering any one of the cells as described in any one of embodiments 41 to 51 to the subject, wherein the isolated cells or cell populations express the chimeric protein, and the chimeric protein comprises the activating CAR as described in embodiment 31.
[0390] Embodiment 58: A method for inhibiting a cell-mediated immune response against tumor cells in a subject, the method comprising administering to a subject having a tumor a therapeutically effective dose of a composition as described in embodiment 36 or embodiment 39, or any of the cells as described in any one of embodiments 41 to 51, or a composition as described in embodiment 52 or embodiment 53.
[0391] Embodiment 59: A method as described in embodiment 58, comprising administering any one of the cells as described in any one of embodiments 41 to 51 to the subject, wherein the isolated cells or cell populations express the chimeric protein, and the chimeric protein comprises the inhibitory CAR as described in embodiment 31.
[0392] Embodiment 60: A method of treating a subject having a tumor, the method comprising administering a therapeutically effective dose of a composition as described in embodiment 36 or embodiment 39, or any of the cells as described in any one of embodiments 41 to 51, or a composition as described in embodiment 52 or embodiment 53.
[0393] Embodiment 61: A kit for treating and / or preventing tumors, the kit comprising the chimeric protein as described in any one of Embodiments 25 to 35.
[0394] Embodiment 62: A kit as described in embodiment 61, wherein the kit further comprises written instructions for using the chimeric protein to produce one or more antigen-specific cells for treating and / or preventing a tumor in a subject.
[0395] Embodiment 63: A kit for treating and / or preventing tumors, the kit comprising the cell or cell population described in any one of Embodiments 41 to 51.
[0396] Embodiment 64: A kit as described in embodiment 63, wherein the kit further comprises written instructions for using the cells to treat and / or prevent a tumor in a subject.
[0397] Embodiment 65: A kit for treating and / or preventing tumors, the kit comprising the engineered nucleic acid as described in Embodiment 41.
[0398] Embodiment 66: A kit as described in embodiment 65, wherein the kit further comprises written instructions for using the nucleic acid to produce one or more antigen-specific cells for treating and / or preventing a tumor in a subject.
[0399] Embodiment 67: A kit for treating and / or preventing tumors, the kit comprising the vector as described in Embodiment 38.
[0400] Embodiment 68: A kit as described in embodiment 67, wherein the kit further comprises written instructions for using the vector to produce one or more antigen-specific cells for treating and / or preventing a tumor in a subject.
[0401] Embodiment 69: A kit for treating and / or preventing tumors, the kit comprising a composition as described in Embodiment 36, Embodiment 39, Embodiment 52 or Embodiment 53.
[0402] Embodiment 70: A kit as described in embodiment 69, wherein the kit further comprises written instructions for using the composition to treat and / or prevent a tumor in a subject.
[0403] Example
[0404] The following are examples of methods and compositions of the present disclosure.It is understood that various other embodiments may be practiced, given the general description provided herein.
[0405] The following are embodiments of specific embodiments for carrying out the subject matter claimed in the present disclosure. These examples are provided for illustrative purposes only and are not intended to limit the scope of the present disclosure in any way. Efforts have been made to ensure the accuracy of the numbers used (e.g., quantity, temperature, etc.), but of course some experimental errors and deviations should be allowed.
[0406] Example 1: Construction of humanized anti-EMCN antigen binding domain
[0407] To generate a humanized anti-EMCN antigen binding domain (eg, scFv), first, the VH and VL sequences from human germline antibodies were aligned with the murine anti-EMCN VH and VL sequences of SEQ ID NO: 63 and SEQ ID NO: 64, respectively. The murine anti-EMCN VH and VL sequences are shown in Table 5.
[0408] Table 5. Murine anti-EMCN VH and VL sequences
[0409]
[0410] Then, the framework regions around the CDRs (as specified by the Kabat annotation and numbering scheme) were replaced with human germline antibody sequences. For the heavy chain human sequences, variable heavy chains 3-23 and 3-33 were selected as framework regions. For the light chain, variable kappa chain 2-30 was selected as framework region. The germline sequences of VH 3-23, VH 3-33, and VK 2-30 are shown in Table 6.
[0411] Table 6. Germline sequences of VH 3-23, VH 3-33 and VK 2-30
[0412]
[0413]
[0414] For humanized VH based on VH 3-33, additional mutations were added to backmutate positions 50 and 52 to the residues present in murine anti-EMCN. Additionally, for humanized VH based on 2-23 and 2-33, CDR-H1 was engineered to match the human germline sequence at positions 3 and 4 of the CDRs as designated by the Chothia annotation and numbering scheme.
[0415] Then, single chain variable fragments (scFv) were engineered using each of the two humanized VH regions ("VH 3-23" and "VH3-33") paired with the humanized VL region ("VL 2-30"). For each VH / VL combination, two orientations (from N-terminus to C-terminus) were constructed, namely VH-peptide linker-VL and VL-peptide linker-VH. For all scFvs, the G4S3 peptide linker was used. The sequences are provided in Table 7.
[0416] Table 7. Humanized anti-EMCN antibody scFv sequences
[0417]
[0418]
[0419]
[0420] Activating chimeric antigen receptor (aCAR) is engineered to include humanized anti-EMCN antigen binding domains. The structure and sequence of the humanized anti-EMCN aCAR produced are shown in Table 8. Each aCAR includes a CD8 signal sequence and a FLAG tag at the N-terminus of the scFV, a CD28 transmembrane (TM) domain, a CD28 intracellular domain (ICD), and a CD3ζ activation domain.
[0421] Table 8. CAR-T containing humanized anti-EMCN scFv
[0422]
[0423]
[0424]
[0425]
[0426] Example 2: Humanized anti-EMCN antigen binding domain maintains binding function in T cell killing assay
[0427] A CAR cell killing assay was performed to assess whether the humanized anti-EMCN antigen binding domain enabled CAR to effectively target cells expressing EMCN. The function of the humanized anti-EMCN scFv was compared to an activating CAR with a parental murine anti-EMCN antigen binding domain.
[0428] The CAR construct as shown in Example 1 is cloned into a retroviral vector. In addition, as a control, an equivalent aCAR containing the antigen binding domain of parental mouse anti-EMCN ("SB02405") is also cloned into a retroviral vector. Then, retrovirus is produced, and the primary T cells previously frozen and separated from human donor PBMC are transduced with retrovirus to express CAR. On the 9th day after transduction, T cells and target cells expressing endothelial mucin are mixed together and co-cultured (ET ratio: 1: 1, 96-well plate, total culture medium volume 200ul). For target cells, two cell lines (SEM and Molm13) of potential cancer targets (e.g., FLT3 (CD135) and CD33 (SIGLEC3)) known to express CAR-mediated killing are each transduced to stably express EMCN. As a control, untransduced SEM cells and untransduced Molm13 are also used. Cells were collected after 18 hours of co-incubation and T cell cytotoxicity against target cells was assessed by flow cytometry (analyzed using FlowJo software) and expressed as percent killing. Figure 1 shown.
[0429] like Figure 1 As shown, aCARs comprising each of the humanized anti-EMCN antigen binding domains induced at least as much or more killing of EMCN-expressing cell lines as compared to a CAR comprising the parental murine anti-EMCN antigen binding domain.
[0430] Example 3: Confirmation of humanized anti-EMCN antigen binding domain function in NK cell killing assay
[0431] The functionality of the humanized anti-EMCN scFv was assessed by T cell killing assay as described in Example 2, and in this example, the functionality was confirmed in a killing assay of NK cells expressing an activating CAR with a humanized anti-EMCN antigen binding domain.
[0432] Retroviruses were generated using each of the retroviral vectors described in Example 2. Primary donor-derived NK cells were transduced with retrovirus to express the CAR. On day 3 after transduction, the expression of the CAR was assessed by flow cytometry based on the FLAG epitope. Day 3 expression of each CAR was as follows: Figure 2 As shown. Figure 2 As shown, the expression of each of the CARs comprising the humanized anti-EMCN antigen binding domain was comparable to that of the CAR comprising the parental antigen binding domain.
[0433] Then, the killing of target cells by CAR NK cells was evaluated. Seven days after transduction, CAR NK cells and target cells expressing endothelial mucin (EMCN-transduced SEM cells, as described in Example 2) were mixed together and co-cultured (ET ratio: 1:1, 96-well plates, total culture medium volume 200ul). As a control, the killing of untransduced SEM cells by NK cells was also evaluated. Cells were collected after 18 hours of co-incubation, and the cytotoxicity of T cells to target cells was evaluated by flow cytometry (analyzed using FlowJo software), which was expressed as a percentage of killing. The results of the killing assay are shown in Figure 2. Figure 3 shown.
[0434] like Figure 3 As shown, NK cells expressing the humanized anti-EMCN NaCAR induced at least as much killing of cell lines expressing EMCN as CARs comprising the parental murine anti-EMCN antigen binding domain.
[0435] Incorporated by Reference
[0436] All publications, patents, patent applications, and other documents cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, patent application, or other document was individually indicated to be incorporated by reference for all purposes.
[0437] Equivalent
[0438] Although various specific embodiments have been illustrated and described, the above description is not restrictive. It should be understood that various changes can be made without departing from the spirit and scope of the present disclosure. After reviewing this specification, many changes will become apparent to those skilled in the art.
Claims
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH comprises a VH complementary region 1 (CDRH1) having an amino acid sequence of SEQ ID NO: 1, a VH complementary region 2 (CDRH2) having an amino acid sequence of SEQ ID NO: 6, and a VH complementary region 3 (CDRH3) having an amino acid sequence of SEQ ID NO: 8; wherein the VL comprises a VL complementary region 1 (CDRL1) having an amino acid sequence of SEQ ID NO: 9, a VL complementary region 2 (CDRL2) having an amino acid sequence of SEQ ID NO: 10, and a VL complementary region 3 (CDRL3) having an amino acid sequence of SEQ ID NO: 11; and wherein the antibody or antigen-binding fragment thereof is humanized.
2. An isolated antibody or antigen-binding fragment thereof that specifically binds to human endothelial mucin (EMCN), the isolated antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH comprises a VH complementary region 1 (CDRH1) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-5, a VH complementary region 2 (CDRH2) having an amino acid sequence of SEQ ID NO: 7, and a VH complementary region 3 (CDRH3) having an amino acid sequence of SEQ ID NO: 8, wherein the VL comprises a VL complementary region 1 (CDRL1) having an amino acid sequence of SEQ ID NO: 9, a VL complementary region 2 (CDRL2) having an amino acid sequence of SEQ ID NO: 10, and a VL complementary region 3 (CDRL3) having an amino acid sequence of SEQ ID NO: 11, and Optionally wherein the antibody or antigen-binding fragment thereof is humanized.
3. The antibody or antigen-binding fragment thereof of claim 1 or claim 2, wherein the VH has an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19, or wherein the VL has an amino acid sequence as shown in SEQ ID NO:
20.
4. The antibody or antigen-binding fragment thereof of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment thereof is an antigen-binding fragment, optionally wherein the antigen-binding fragment comprises a F(ab) fragment, a F(ab') fragment or a single-chain variable fragment (scFV), optionally wherein the antigen-binding fragment comprises a single-chain variable fragment (scFv).
5. The antibody or antigen-binding fragment thereof of any one of claims 1 to 4, wherein the VH and the VL of the scFv are separated by a peptide linker, optionally wherein the antigen-binding domain comprises the structure VH-L-VL or VL-L-VH, wherein VH is a heavy chain variable domain, L is the peptide linker, and VL is a light chain variable domain, optionally wherein the peptide linker comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs: 21-37. 6 . The antibody or antigen-binding fragment thereof according to claim 1 , wherein the scFv comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 65, 67, 69 and 70. 7 .
7. A chimeric protein comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, and a heterologous molecule or part; Optionally wherein the chimeric protein is an antibody-drug conjugate, and wherein the heterologous molecule or moiety comprises a therapeutic agent; Optionally wherein the chimeric protein is a chimeric antigen receptor (CAR), and wherein the heterologous molecule or moiety comprises a polypeptide selected from the group consisting of a transmembrane domain, one or more intracellular signaling domains, a hinge domain, a spacer, one or more peptide linkers, and combinations thereof, optionally wherein the CAR comprises a transmembrane domain; Optionally wherein the CAR comprises one or more intracellular signaling domains, optionally wherein the CAR is an activating CAR comprising one or more intracellular signaling domains that stimulate an immune response; optionally wherein the CAR is an inhibitory CAR comprising one or more intracellular inhibitory domains that inhibit an immune response, optionally wherein the intracellular inhibitory domain comprises an enzyme inhibitory domain; Optionally wherein the intracellular inhibitory domain comprises an intracellular inhibitory co-signaling domain; Optionally wherein the CAR comprises a spacer between the antigen binding domain and the transmembrane domain; Optionally wherein the spacer has an amino acid sequence selected from the group consisting of SEQ ID NOs: 41-52.
8. An engineered nucleic acid encoding the antibody or antigen-binding fragment of any one of claims 1 to 6 or the chimeric protein of claim 7.
9. An expression vector comprising the engineered nucleic acid of claim 8.
10. A composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, the chimeric protein according to claim 7, the engineered nucleic acid according to claim 8, or the expression vector according to claim 9, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof.
11. A method for preparing an engineered cell, the method comprising transducing an isolated cell with the engineered nucleic acid of claim 8 or the expression vector of claim 9.
12. An isolated cell comprising the antigen-binding fragment of any one of claims 1 to 6, the chimeric protein of claim 7, the engineered nucleic acid of claim 8, the expression vector of claim 9, or the composition of claim 10.
13. An engineered cell population expressing the engineered nucleic acid of claim 8, the expression vector of claim 9, the antigen-binding fragment of any one of claims 1 to 6, or the chimeric protein of claim 7.
14. The cell or cell population of claim 12 or claim 13, wherein the chimeric protein is recombinantly expressed; Optionally wherein the chimeric protein is expressed from a vector or a selected locus in the genome of the cell; Optionally wherein the cell or cell population further comprises one or more tumor-targeting chimeric receptors expressed on the surface of the cell; Optionally, wherein each of the one or more tumor-targeting chimeric receptors is a chimeric antigen receptor (CAR) or an engineered T cell receptor; Optionally wherein the cell or cell population is selected from the group consisting of: T cells, CD8+T cells, CD4+T cells, γ-δT cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, virus-specific T cells, natural killer T (NKT) cells, natural killer (NK) cells, B cells, tumor infiltrating lymphocytes (TILs), innate lymphoid cells, mast cells, eosinophils, basophils, neutrophils, bone marrow cells, macrophages, monocytes, dendritic cells, erythrocytes, platelet cells, human embryonic stem cells (ESCs), ESC-derived cells, pluripotent stem cells, mesenchymal stromal cells (MSCs), induced pluripotent stem cells (iPSCs) and iPSC-derived cells, optionally wherein the cells are autologous, optionally wherein the cells are allogeneic.
15. A pharmaceutical composition comprising an effective amount of the isolated cells of claim 12 or the engineered cell population of claim 13, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof; or an effective amount of genetically modified cells, the genetically modified cells expressing the antigen binding fragment of any one of claims 1 to 6 or the chimeric protein of claim 7 and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, or a combination thereof, optionally wherein the pharmaceutical composition is used to treat and / or prevent tumors.
16. A method of treating a subject in need thereof, the method comprising administering a therapeutically effective dose of the composition of claim 10, or the isolated cells of claim 12, or the pharmaceutical composition of claim 15.
17. A method of inhibiting a cell-mediated immune response against tumor cells in a subject, the method comprising administering a therapeutically effective dose of the composition of claim 10, or the isolated cells of claim 12, to a subject having a tumor, optionally wherein the isolated cells or cell populations express a chimeric protein, the chimeric protein comprising the chimeric protein of claim 7.
18. A method of treating a subject having a tumor, the method comprising administering a therapeutically effective dose of the composition of claim 10, or the isolated cells of claim 12, or the composition of claim 10.
19. A kit for treating and / or preventing a tumor, the kit comprising the chimeric protein of claim 7; the isolated cell of claim 12 or the cell population of claim 13; the engineered nucleic acid of claim 12; the expression vector of claim 13; the composition of claim 10; optionally wherein the kit further comprises written instructions for using the cell to treat and / or prevent a tumor in a subject; Optionally wherein the kit further comprises written instructions for using the nucleic acid to generate one or more antigen-specific cells for treating and / or preventing a tumor in a subject; Optionally wherein the kit further comprises written instructions for using the vector to produce one or more antigen-specific cells for treating and / or preventing a tumor in a subject; Optionally, the kit further comprises written instructions for using the composition to treat and / or prevent a tumor in a subject; or optionally, the kit further comprises written instructions for using the chimeric protein to produce one or more antigen-specific cells for treating and / or preventing a tumor in a subject.
